Introduction

Cardiovascular Disease (CVD)

Atherosclerosis: Overview and Statistics

Overview

Atherosclerosis: Overview and Statistics

Overview
Statistics

Prevalence and Incidence of CVD

Statistics: Cardiovascular Disease (CVD)

Relationship between Obesity, Diabetes and Cardiovascular Disease

Obesity, Diabetes and Cardiovascular Disease

Atherosclerosis: Overview and Statistics

Statistics

Relationship between Obesity, Diabetes, and Cardiovascular Disease

Obesity, Diabetes and Cardiovascular Disease

Prevalence and Incidence of CVD

Prevalence and Incidence of Cardiovascular Disease (CVD): Overview

Atherosclerosis: Overview and Statistics

Statistics

Atherosclerosis: Treatments

Intervention - Medications

Atherosclerosis: Overview and Statistics

Overview

Atherosclerosis: Overview and Statistics

Overview

Pathophysiology

Cardiovascular

Atherosclerosis: Treatments

Intervention - Medications

GLP-1 Receptor Agonists and Cardiovascular Events

GLP-1 Receptor Agonists: Effect of on Cardiovascular Events

Atherosclerosis: Treatments

Treatment of Atherosclerosis - Overview
Intervention - Medications
Intervention - Invasive...

Relationship between Obesity, Diabetes and Cardiovascular Disease

Obesity, Diabetes and Cardiovascular Disease
Obesity: Pathophysiology of Fat Cells
Obesity...

Introduction

Overview
Cardiovascular Disease (CVD)
Routine Treatments
New Therapies

Residual Risk

Common Complications: Cardiovascular

Lymphatic System

Lymphatic System
Interactivity: Cardiovascular System Functions

Relationship between Obesity, Diabetes, and Cardiovascular Disease

Obesity and Insulin Resistance
Obesity and Dyslipidemia
Obesity and Hypertension
Obes...

Heart Failure: Overview and Statistics

Heart Failure Introduction
Overview
Statistics

Economic Burden of AF

Total AF, Other Cardiovascular, and Noncardiovascular Costs

Relationship between Obesity, Diabetes and Cardiovascular Disease

Obesity and Cardiovascular Mortality

Heart Failure: Overview and Statistics

Statistics

Heart Failure: Overview and Statistics

Overview

Heart Failure: Overview and Statistics

Statistics

Heart Failure: Overview and Statistics

Overview

Atherosclerosis: Treatments

Intervention - Medications

Heart Failure: Treatments

Emerging Therapies

Atherosclerosis Contribution to Cardiovascular Diseases

Atherosclerosis Contribution to Cardiovascular Diseases: Overview

Complications

Cardiovascular

Heart Failure: Treatments

Overview
Prevention
Treatment Guidelines
Intervention - Medications
ACE Inhibito...

Atherosclerosis: Overview and Statistics

Overview

Atherosclerosis: Overview and Statistics

Statistics

Atherosclerosis: Overview and Statistics

Statistics

Atherosclerosis: Overview and Statistics

Statistics

Phase III Clinical Studies

Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND)

Clinical Trials: Cardiovascular Outcomes for Diabetes Drugs

Common Outcomes in Diabetes Trials

Additional Recommendations and Position Statements

American Diabetes Association (ADA) Position Statement: Cardiovascular Disease and Risk Management

Prevalence and Incidence of CVD

Statistics

2013 ACC/AHA Guidelines on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults

Four Statin Benefit Groups

Complications/Comorbidities of SLE

Cardiovascular Disease (CVD)

Atherosclerosis: Risk Factors

Risk Factors

Atherosclerosis: Risk Factors

Risk Factors

Atherosclerosis: Risk Factors

Risk Factors

Venous Thromboembolism (VTE) Clinical Picture

Comorbid States: Cardiovascular Disease and Acute Myocardial Infarction (AMI)

Prevalence and Incidence of CVD

Statistics: Mortality

Relationship between Obesity, Diabetes and Cardiovascular Disease

Obesity and Youth

Cardiovascular Measures

Electrocardiogram, Endpoints for Diabetes Studies: MACE

Atherosclerosis Contribution to Cardiovascular Diseases

Coronary Artery Disease

Atherosclerosis Contribution to Cardiovascular Diseases

Coronary Artery Disease: Myocardial Infarction

Atherosclerosis Contribution to Cardiovascular Diseases

Coronary Artery Disease: Heart Failure

Atherosclerosis Contribution to Cardiovascular Diseases

Coronary Artery Disease: Sudden Death

Atherosclerosis Contribution to Cardiovascular Diseases

Transient Ischemic Attack (TIA)

Atherosclerosis Contribution to Cardiovascular Diseases

Ischemic Stroke

Atherosclerosis Contribution to Cardiovascular Diseases

Peripheral Arterial Disease (PAD)

Atherosclerosis Contribution to Cardiovascular Diseases

Hypertension Secondary to Atherosclerosis

Heart Failure: Risk Factors

Risk Factors

Heart Failure: Treatments

Intervention - Medications
ACE Inhibitors
Angiotensin Receptor Blockers
β-Blocke...

Controversies in Androgen Replacement Therapy

Cardiovascular

Atherosclerosis: Causes

Atherogenesis
Fatty Streak
Inflammation
Leukocyte Recruitment
Foam Cell Formatio...

Role of the Heart and Circulatory System

Location

Role of the Heart and Circulatory System

Cardiac Conduction

Role of the Heart and Circulatory System

Role of Circulation

The Heart and Circulation: Anatomy

Heart

The Heart and Circulation: Anatomy

Heart - Endocardium

The Heart and Circulation: Anatomy

Heart - Epicardium

The Heart and Circulation: Anatomy

Heart
Heart - Endocardium
Heart - Myocardium
Heart - Epicardium

Atherosclerosis: Diagnostic Tools/Biomarkers

MRI

Atherosclerosis: Causes

Atherogenesis

Atherosclerosis: Causes

Fatty Streak

Atherosclerosis: Causes

Inflammation

Atherosclerosis: Causes

Leukocyte Recruitment

Atherosclerosis: Causes

Foam Cell Formation

Atherosclerosis: Causes

Atheroma Evolution

Atherosclerosis: Causes

Plaque Rupture

Atherosclerosis: Causes

Thrombus Formation

Atherosclerosis: Complications

Overview

Atherosclerosis: Complications

Coronary Artery Disease

Atherosclerosis: Complications

Ischemic Stroke

Atherosclerosis: Complications

Peripheral Arterial Disease (PAD)

Atherosclerosis: Treatments

Intervention - Medications

Atherosclerosis: Treatments

Intervention - Medications

Atherosclerosis: Treatments

Emerging Therapies

Heart Failure: Overview and Statistics

Overview

Heart Failure: Overview and Statistics

Statistics

Heart Failure: Overview and Statistics

Statistics

Heart Failure: Risk Factors

Risk Factors

Heart Failure: Risk Factors

Risk Factors

Heart Failure: Diagnostic Tools/Biomarkers

MRI

Heart Failure: Diagnostic Tools/Biomarkers

Biomarkers

Heart Failure: Diagnostic Tools/Biomarkers

Biomarkers

Heart Failure: Diagnostic Tools/Biomarkers

Biomarkers

Heart Failure: Causes

Index Event
Nature of Index Event
Compensatory Mechanisms
Left Ventricular Remodeling

Heart Failure: Causes

Index Event

Heart Failure: Causes

Compensatory Mechanisms

Heart Failure: Causes

Compensatory Mechanisms

Heart Failure: Causes

Compensatory Mechanisms

Heart Failure: Causes

Compensatory Mechanisms

Heart Failure: Complications

Overview

Heart Failure: Treatments

Overview

Heart Failure: Treatments

Prevention

Heart Failure: Treatments

Treatment Guidelines

Heart Failure: Treatments

Intervention - Medications

Heart Failure: Treatments

ACE Inhibitors

Heart Failure: Treatments

β-Blockers

Heart Failure: Treatments

Diuretics

Heart Failure: Treatments

Aldosterone Antagonists

Heart Failure: Treatments

Vasodilators

Heart Failure: Treatments

Implantable Defibrillator

Heart Failure: Treatments

Heart Transplant

Heart Failure: Treatments

Prognosis

Atherosclerosis: Complications

Overview
Coronary Artery Disease
Transient Ischemic Attack (TIA)
Ischemic Stroke

Heart Failure: Diagnostic Tools/Biomarkers

Physical Examination
Routine Laboratory Testing
Electrocardiogram (ECG)
Chest X-Ray

Atherosclerosis: Treatments

Intervention - Invasive Techniques

Heart Failure: Treatments

Intervention - Invasive Techniques
Implantable Defibrillator
Cardiac Resynchronization The...

Atherosclerosis: Treatments

Treatment of Atherosclerosis - Overview

Glycemic Control Intervention in Type 2 Diabetes: Heart2D

Hyperglycemia and its Effect after Acute myocardial infaRction on cardiovascular outcomes in patient...

Atherosclerosis: Diagnostic Tools/Biomarkers

Laboratory Studies
Coronary Angiography
Intravascular Ultrasound
Computed Tomography

Heart Failure: Complications

Overview
Systolic Dysfunction (Reduced LV Ejection Fraction)
Diastolic Dysfunction (Preser...

Atherosclerosis Contribution to Cardiovascular Diseases

Renal Artery Disease and Secondary Hypertension

2013 ACC/AHA Guidelines on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults

Statin Safety Recommendations

2013 ACC/AHA Guidelines on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults

Areas of Controversy

Role of the Heart and Circulatory System

Self Checks: Lungs, Heart. Vessels
Location
Appearance
Heart is a Double Pump
Ca...

The Heart and Circulation: Anatomy

AV Valves - Tricuspid Valve
AV Valves - Mitral Valve

The Heart and Circulation: Anatomy

Semilunar Valves - Aortic Valve
Semilunar Valves - Pulmonary Valve

The Heart and Circulation: Physiology

Conduction Sinus Node
Conduction - AV Node

Role of the Heart and Circulatory System

Appearance

Role of the Heart and Circulatory System

Heart is a Double Pump

Role of the Heart and Circulatory System

Cardiac Cycle

Role of the Heart and Circulatory System

Cardiac Muscle

Role of the Heart and Circulatory System

Arteries, Veins, and Capillaries

The Heart and Circulation: Anatomy

Overview
Chambers Right Atrium
Chambers Right Ventricle
Chambers Left Atrium
...

The Heart and Circulation: Anatomy

Overview

The Heart and Circulation: Anatomy

Chambers Right Ventricle

The Heart and Circulation: Anatomy

Chambers Left Ventricle

The Heart and Circulation: Anatomy

Chordae Tendineae

The Heart and Circulation: Anatomy

Papillary Muscles

The Heart and Circulation: Anatomy

Semilunar Valves - Aortic Valve

The Heart and Circulation: Anatomy

Semilunar Valves - Pulmonary Valve

The Heart and Circulation: Anatomy

Heart - Myocardium

The Heart and Circulation: Physiology

Cardiac Conduction - Overview

The Heart and Circulation: Physiology

Conduction Sinus Node

The Heart and Circulation: Physiology

Conduction - AV Node

The Heart and Circulation: Physiology

His-Purkinje System

The Heart and Circulation: Physiology

Cardiac Ion Channels

The Heart and Circulation: Physiology

Cardiac Output

The Heart and Circulation: Physiology

Stroke Volume

The Heart and Circulation: Physiology

Ejection Fraction

Atherosclerosis: Diagnostic Tools/Biomarkers

Coronary Angiography

Atherosclerosis: Diagnostic Tools/Biomarkers

Intravascular Ultrasound

Atherosclerosis: Diagnostic Tools/Biomarkers

Computed Tomography

Atherosclerosis: Diagnostic Tools/Biomarkers

Nuclear Medicine Techniques

Atherosclerosis: Causes

High-Risk Atherothrombotic Plaque

Atherosclerosis: Causes

Involvement of Platelets

Atherosclerosis: Causes

Platelet Activation

Atherosclerosis: Complications

Coronary Artery Disease

Atherosclerosis: Complications

Coronary Artery Disease

Atherosclerosis: Complications

Transient Ischemic Attack (TIA)

Atherosclerosis: Treatments

Intervention - Medications

Atherosclerosis: Treatments

Intervention - Medications

Atherosclerosis: Treatments

Intervention - Invasive Techniques

Atherosclerosis: Treatments

Intervention - Invasive Techniques

Atherosclerosis: Treatments

Intervention - Invasive Techniques

Heart Failure: Diagnostic Tools/Biomarkers

Physical Examination

Heart Failure: Diagnostic Tools/Biomarkers

Routine Laboratory Testing

Heart Failure: Diagnostic Tools/Biomarkers

Electrocardiogram (ECG)

Heart Failure: Diagnostic Tools/Biomarkers

Chest X-Ray

Heart Failure: Causes

Nature of Index Event

Heart Failure: Causes

Left Ventricular Remodeling

Heart Failure: Causes

Left Ventricular Remodeling

Heart Failure: Causes

Left Ventricular Remodeling

Heart Failure: Complications

Congestion/Fluid Retention

Heart Failure: Complications

Acute Heart Failure

Heart Failure: Complications

Stages of Heart Failure

Heart Failure: Treatments

Angiotensin Receptor Blockers

Heart Failure: Treatments

Digitalis Glycosides (Digoxin)

Heart Failure: Treatments

Intervention - Invasive Techniques

Heart Failure: Treatments

Cardiac Resynchronization Therapy

Atherosclerosis: Complications

Coronary Artery Disease

The Heart and Circulation: Physiology

Cardiac Conduction - Overview
Conduction Sinus Node
Conduction - AV Node
His-Purkinj...

Relationship between Obesity, Diabetes and Cardiovascular Disease

Prevalence of Obesity in Adults Aged 20+ Years by WHO Region (2008)
Obesity and Type 2 Diabetes...

The Heart and Circulation: Anatomy

Chambers Right Atrium

The Heart and Circulation: Anatomy

Chambers Left Atrium

The Heart and Circulation: Anatomy

Chambers Right Atrium
Chambers Right Ventricle
Chambers Left Atrium
Chambers Left...

The Heart and Circulation: Anatomy

AV Valves - Tricuspid Valve

The Heart and Circulation: Anatomy

AV Valves - Mitral Valve

The Heart and Circulation: Anatomy

Coronary Arteries - Overview

The Heart and Circulation: Anatomy

Coronary Arteries - Intima

The Heart and Circulation: Anatomy

Coronary Arteries - Media

The Heart and Circulation: Anatomy

Coronary Arteries - Adventitia

The Heart and Circulation: Physiology

Pressure-Volume Loops/Relationships

Atherosclerosis: Diagnostic Tools/Biomarkers

Laboratory Studies

Atherosclerosis: Treatments

Intervention - Invasive Techniques

Atherosclerosis: Treatments

Intervention - Invasive Techniques

Heart Failure: Diagnostic Tools/Biomarkers

2-D Echocardiogram/Doppler

Heart Failure: Complications

Systolic Dysfunction (Reduced LV Ejection Fraction)

Heart Failure: Complications

Diastolic Dysfunction (Preserved LV Ejection Fraction)

Heart Failure: Treatments

Left Ventricular Assist Device (LVAD)

Complications

Oxygen Toxicity
Pulmonary Barotrauma/Volutrauma
Cardiovascular
Other Complications

2013 ACC/AHA Guidelines on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults

Primary Prevention in Individuals ≥21 Years of Age With LDL-C ≥190 mg/dL Without ASCVD

2013 ACC/AHA Guidelines on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults

Primary Prevention in Individuals With Diabetes Without Clinical ASCVD

2013 ACC/AHA Guidelines on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults

Primary Prevention in Individuals Without Diabetes and With LDL-C 70-189 mg/dL

The Heart and Circulation: Anatomy

Coronary Arteries - Overview
Coronary Arteries - Intima
Coronary Arteries - Media
Cor...

The Heart and Circulation: Physiology

Fractional Shortening

The Heart and Circulation: Physiology

Fractional Shortening

The Heart and Circulation: Physiology

Fractional Shortening

Association of Obesity, Diabetes, and Cardiovascular Disease

Obesity Trends Among U.S. Adults (BRFSS)

Relationship between Obesity, Diabetes and Cardiovascular Disease

Obesity

Cardiovascular Measures

Heart Failure in T2DM

Relationship between Obesity, Diabetes and Cardiovascular Disease

Obesity: Pathophysiology of Fat Cells

Relationship between Obesity, Diabetes and Cardiovascular Disease

Obesity and Diabetes Risk

Relationship between Obesity, Diabetes and Cardiovascular Disease

Obesity and the Metabolic Syndrome

Relationship between Obesity, Diabetes, and Cardiovascular Disease

Obesity and Insulin Resistance

Relationship between Obesity, Diabetes, and Cardiovascular Disease

Obesity and Dyslipidemia

Relationship between Obesity, Diabetes, and Cardiovascular Disease

Obesity and Hypertension

Relationship between Obesity, Diabetes, and Cardiovascular Disease

Worldwide Rates of Overweight and Obesity

Relationship between Obesity, Diabetes and Cardiovascular Disease

Obesity and Type 2 Diabetes: Adults

Relationship between Obesity, Diabetes and Cardiovascular Disease

Obesity and Type 2 Diabetes: Youth

Relationship between Obesity, Diabetes and Cardiovascular Disease

Overweight and Obesity in Youth

Phase III Clinical Studies

Dulaglutide and Risk for Cardiovascular Events

Relationship between Obesity, Diabetes and Cardiovascular Disease

Prevalence of Obesity in Adults Aged 20+ Years by WHO Region (2008)

Blood

Plasma

Introduction

Routine Treatments

Learning Objectives

Learning Objectives

Learning Objectives

Learning Objectives

Introduction

Platelet Development Pathway

Platelet Receptor Physiology

Thromboxane A2

Measures of Platelet Aggregation

Light Transmission Aggregometry: Effects Shown

Learning Objectives

Learning Objectives

Introduction and Learning Objectives

Introduction and Learning Objectives

Complications of Atrial Fibrillation (AF)

Overview

Blood Vessels

Types of Blood Vessels

Introduction and Learning Objectives

Introduction and Learning Objectives

Venous Thromboembolism (VTE) Clinical Picture

Summary of Epidemiology

Introduction

Introduction

Introduction and Learning Objectives

Introduction and Learning Objectives

Statins

Efficacy and Safety: Secondary Prevention

Introduction

Overview

ACC/AHA Treatment Guidelines for ACS: Statistics

Prevalence and Incidence: CVD Statistics

Atherothrombosis

Platelets and Development of Atherosclerotic Lesions: Platelet Interaction with Endothelial Cells

Introduction

Introduction

Introduction

Introduction and Learning Objectives

Diagnosis and Monitoring

Overview

Vascular Anatomy

Introduction: Vascular Anatomy

Anatomy of the Heart

Overview: The Heart

Ticlopidine

Ticlopidine: Overview

Blood Vessels

Major Circulatory Systems

Atrial Fibrillation (AF)

Overview: Atrial Fibrillation

Introduction: Interventional Cardiology

Interventional Cardiology: Definition and Advantages

Blood

Composition

Heart

Regulation of CV Function

Hemostasis

Control of Hemostatic Pathways

Platelet Receptor Physiology

ADP

Anticoagulant Reversal Agents

Summary of Anticoagulation Reversal Agents

Introduction

Introduction and Learning Objectives

Introduction to Heart Failure

Introduction and Learning Objectives

Treatment Guidelines: Introduction

Treatment Guidelines: Introduction

Blood

Hematopoiesis

Blood

Blood Volume

Venous Thromboembolism (VTE) Clinical Picture

Incidence and Age

Complications of Atrial Fibrillation (AF)

Thromboembolic Complications

Coronary Atherosclerosis: Overview

Risk Factors on the Rise

Drug Therapy in ACS: Overview

Inhibitors of Renin-Angiotensin System

Atherothrombosis

Platelets and Arterial Thrombosis: Causes of Plaque Disruption

Measures of Platelet Aggregation

Overview: Platelets

Bleeding in ACS: Clinical Definition of Bleeding

Classification of Bleeding

Drug Therapy in ACS: Overview

STEMI: Analgesia

Introduction: Interventional Cardiology

Interventional Cardiology: Embolic Protection and Percutaneous Heart Valve Interventions

Introduction: Interventional Cardiology

Coronary Angiography: Left Coronary Angiogram

Introduction: Interventional Cardiology

Coronary Angiography: Left Coronary Angiogram in the Right Anterior Oblique

Selected Basal Insulin Clinical Trials

DEVOTE

Blood

Blood Volume

Clinical Implications of Clot Formation

Arterial and Venous Thrombosis

Ezetimibe (Zetia)

Efficacy and Safety: IMPROVE-IT Trial

Niacin (Nicotinic Acid)

Efficacy and Safety: Niacin Therapy

BED Disease State

Metabolic Syndrome Components: Dyslipidemia, Hypertension, and Type 2 Diabetes

Phase III Clinical Studies

Phase III Development Program

Clopidogrel Clinical Trials

CURE Study

Management of Patients with Atrial Fibrillation

Management Goals and Factors to Consider

Pathophysiology of Atrial Fibrillation

Atrial Fibrillation Maintaining Mechanisms

VTE Clinical Picture: Epidemiology

Summary of Epidemiology

Heart

Functions: Blood Collection

Cardiac Cycle

Integrated Review

Hemostasis

Fibrinolysis

Atherothrombosis

Involvement of Platelets

Measures of Platelet Aggregation

Light Transmission Aggregometry: Overview

Pathophysiology of Atherothrombosis: Overview

Atherogenesis: Overview

ACC/AHA Treatment Guidelines for ACS: Statistics

Diagnosis by Clinician: UA/NSTEMI

Drug Therapy in ACS: Overview

Drug Therapy in ACS: Overview

Drug Therapy in ACS: Overview

Drug Therapy in ACS: ACC/AHA Guidelines

Drug Therapy in ACS: Overview

Thienopyridines Approved for Antiplatelet Therapy

Drug Therapy in ACS: Overview

Approved GP IIb/IIIa Antagonists

Bleeding in ACS: Clinical Definition of Bleeding

Incidence of Bleeding

Bleeding in ACS: Clinical Definition of Bleeding

Transfusion Risks

Introduction: Interventional Cardiology

Coronary Angiography

Introduction: Interventional Cardiology

Coronary Angiography: Normal Left Coronary Angiogram

Introduction: Interventional Cardiology

Coronary Angiography: Right Coronary Angiogram

Introduction: Interventional Cardiology

Coronary Angiography: Left Ventricular Angiogram

Introduction: Interventional Cardiology

Coronary Artery Bypass Graft (CABG) Surgery

Percutaneous Coronary Intervention (PCI)

Mechanism of Revascularization

Percutaneous Coronary Intervention (PCI)

The Point of Access for PCI

Intracoronary Stents

Overview: Stent Implantation

Intracoronary Stents

Bare Metal Stents (BMS)

Intracoronary Stents

Drug-Eluting Stents (DES): Restenosis

Stent Thrombosis

Drug-Eluting Stents (DES)

Stent Thrombosis

Duration of Dual Antiplatelet Therapy: Clopidogrel

Role of the Heart and Circulatory System

Overview: Heart and Circulatory System

Anatomy of the Heart

Heart: Three Layers

Anatomy of the Heart

Heart: Endocardium

Anatomy of the Heart

Heart: Epicardium

Cardiac Cycle

Pressure-Volume Loops/Relationships: Variables in Ventricular Function

Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) Diagnosis and Treatment Guidelines

DVT and PE Diagnosis Guidelines

Pathophysiology of Atrial Fibrillation

Atrial Fibrosis

Clopidogrel Clinical Trials

PCI-CURE Study

Thienopyridines

Prasugrel

Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) Diagnosis and Treatment Guidelines

VTE Diagnosis: Clinical Methods

Disease State

Etiology of Hyperlipidemia - Secondary

Insulin Glargine: Lantus

The Outcome Reduction with Initial Glargine Intervention trial (ORIGIN)

Phase 3 Clinical Studies

Dulaglutide: REWIND

Drug Therapy in ACS: Overview

UA/NSTEMI: Analgesic Therapy: Morphine

Causes of Atrial Fibrillation (AF), Associated Conditions

Associated Heart Disease

Causes of Atrial Fibrillation

Reversible Conditions and Associated Heart Disease

Treatment Goals and Modalities

2013 ACC/AHA Guidelines on the Treatment of Blood Cholesterol to Reduce ASCVD Risk in Adults

Special Populations

NLA: Hispanics/Latinos

Definition of Venous Thromboembolism (VTE)

Impaired Gas Exchange During Pulmonary Embolism (PE) and Upper Extremity DVT

Clopidogrel Clinical Trials

PCI-CLARITY Study

Major Adverse Cardiac Events (MACE)

Major Adverse Cardiac Events (MACE)

Causes of Atrial Fibrillation

Causes of Atrial Fibrillation: Overview

VTE Prevention Guidelines

Prevention in Surgical Patients: Orthopedic Surgery

Complications of Atrial Fibrillation (AF)

Thromboembolic Complications: Transient Ischemic Attacks and Stroke

Diabetes Clinical Trials Studying Complications

DCCT/EDIC Study

Blood Vessels

Structure and Function

Blood Vessels

Structure and Function: Tunica Adventitia

Heart

Cardiac Myocytes: Sarcomeres and Myofibrils

Heart

Cardiac Myocytes: Myofilaments

Heart

Cardiac Conduction System: Overview

Heart

Cardiac Conduction System: Cardiac Rate Control

Heart

Location

Heart

Pericardium

Heart

Cardiac Myocytes: Characteristics

Cardiac Cycle

Electrocardiogram (ECG): P Wave, PR Interval, QRS Complex

Introduction

Platelets

Hemostasis

Overview: Hemostasis

Hemostasis

Clot Retraction and Vessel Repair

Hemostasis

Disorders of Hemostasis: Abnormal Bleeding

Hemostasis

Platelet Aggregation

Hemostasis

Hemostasis

Atherothrombosis

Overview: Atherothrombosis

Atherothrombosis

Overview: Atherosclerotic Process

Atherothrombosis

Platelets and Development of Atherosclerotic Lesions

Platelet Receptor Physiology

ADP and Thromboxane A2

Platelet Receptor Physiology

IIb/IIIa and Platelet Aggregation

Platelet Receptor Physiology

IIb/IIIa as a Target

Measures of Platelet Aggregation

VerifyNow: Overview

Measures of Platelet Aggregation

Measure of Platelet Biomarkers VASP: PGE-1

Measures of Platelet Aggregation

Light Transmission Aggregometry: MPA & IPA

Measures of Platelet Aggregation

Point-of-Care Devices

Clopidogrel

Genetic Variation

Stent Thrombosis

Clopridogrel Resistance and Poor Response

Coronary Atherosclerosis: Overview

Genetic Predisposition

Pathophysiology of Atherothrombosis: Overview

Atherogenesis: Lesion

Pathophysiology of Atherothrombosis: Overview

Plaque Rupture

Acute Coronary Syndrome (ACS): Overview

Pathogenesis of ACS

ACC/AHA Treatment Guidelines for ACS: Statistics

Diagnosis by Clinician: Treatment of UA/NSTEMI

Drug Therapy in ACS: Overview

Thienopyridines: Adenosine Diphosphate (ADP) Receptor (P2Y12) Antagonists

Drug Therapy in ACS: Overview

GP IIb/IIIa Antagonists

Drug Therapy in ACS: Overview

Unfractionated Heparin (UFH)

Drug Therapy in ACS: Overview

STEMI: Reperfusion

Bleeding in ACS: Clinical Definition of Bleeding

Clinical Consequences of Bleeding

Introduction: Interventional Cardiology

Cardiac Catheterization: Historical Perspective

Introduction: Interventional Cardiology

Coronary Balloon Angioplasty

Percutaneous Coronary Intervention (PCI)

Percutaneous Coronary Intervention (PCI): Indications

Intracoronary Stents

Intracoronary Stents: Overview

Intracoronary Stents

Balloon Angioplasty and Intracoronary Stent Placement: Balloon Inflation in LAD

Intracoronary Stents

Balloon Angioplasty and Intracoronary Stent Placement: LAD After Stent Insertion and Balloon Dilatat...

Intracoronary Stents

Drug-Eluting Stents (DES): Thienopyridine and Aspirin

Intracoronary Stents

Adjunctive Drug Therapy: Heparin

Stent Thrombosis

Stent Thrombosis: Use in Patients with PCI

Stent Thrombosis

Timing and Incidence: Acute/Subacute Stent Thrombosis

Stent Thrombosis

Bare Metal Stents (BMS)

Stent Thrombosis

Risk Factors: Early and Late Stent Thrombosis

Stent Thrombosis

Very Late Stent Thrombosis

Stent Thrombosis

Duration of Dual Antiplatelet Therapy: Premature Cessation

Stent Thrombosis

Duration of Dual Antiplatelet Therapy: Incidence and Predictors

Anatomy of the Heart

Introduction: The Heart

Anatomy of the Heart

Heart: Myocardium

Cardiac Cycle

Stroke Volume

Cardiac Conduction

Introduction: Cardiac Conduction

Clot Formation

Secondary Hemostasis: Coagulation Cascade

Causes of Atrial Fibrillation (AF), Associated Conditions

Causes of Atrial Fibrillation (AF): Overview

Pathophysiology of Atrial Fibrillation (AF)

Mechanisms of Atrial Fibrillation (AF): Abnormal Electrical and Ectopic Impulse Conduction

Venous Thromboembolism (VTE) Clinical Picture

Incidence: Other Factors

Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) Diagnosis and Treatment Guidelines

VTE Treatment Guidelines: Overview

Introduction

New Therapies

VTE Clinical Picture: Risk Factors and Comorbid States

Comorbid States

Diagnosis and Monitoring

Risk Assessment and Screening

Definition of Venous Thromboembolism (VTE)

Venous Thromboembolism (VTE) Location and the Relationship between DVT and PE

Anatomy of the Heart

Introduction: The Heart
Overview: The Heart
Chambers: Right and Left Atrium, Right and Lef...

Selected Basal Insulin Clinical Trials

Glargine vs. Standard of Care

Special Populations

NLA: Children and Adolescents

Statins

Efficacy and Safety: Primary Prevention

Macrovascular Complications

Blood Pressure, Dyslipidemia

Insulin Glargine: Lantus

Safety

BED Disease State

Metabolic Syndrome and Metabolic Risk Factors

Coronary Atherosclerosis: Overview

Risk Factors and Atherosclerosis

Male Reproductive Physiology

Testosterone

Clopidogrel Clinical Trials

CHARISMA Study

Pathophysiology of Atrial Fibrillation (AF)

Atrial Fibrosis

Clinical Prevention

Primary Prevention

Treatment and Prevention of Cancer-associated VTE

Surgery Patients

Epidemiology and Natural History

Prevalence of Organ System Involvement in the HOS

Blood

Composition
Functions: Transportation, Regulation, Protection
Functions: Red Blood Cells, ...

Typical Clinical Course

Organ Systems Involved

Introduction: Atrial Fibrillation

Introduction: Atrial Fibrillation

Thromboembolic Complications

Risk Stratification: CHADS2 Limitations

Management of Patients with Atrial Fibrillation

Rate Control: Pharmacological Therapy

Management of Patients with Atrial Fibrillation

Preventing Thromboembolism: Anticoagulation

Introduction

Introduction: Venous Thromboembolism

VTE Prevention Guidelines

Venous Thromboembolism (VTE) Prophylaxis

VTE Prevention Guidelines

ACCP, AAOS, ASRA Compendium of Consensus Recommendations for VTE Prophylaxis

VTE Prevention Guidelines

Prevention in Surgical Patients: Non-Orthopedic Surgery

VTE Prevention Guidelines

Special Situations and Procedures for High Risk of Bleeding

Blood

Functions: Transportation, Regulation, Protection

Blood

Functions: Red Blood Cells, White Blood Cells, and Platelets

Blood Vessels

Structure and Function: Tunica Media

Lymphatic System

Lymphatic System

Heart

Cardiac Myocytes: Intercalated Discs

Heart

Cardiac Myocytes: Action Potentials

Heart

Left and Right Sides

Heart

Coronary Vasculature

Cardiac Cycle

Overview

Cardiac Cycle

Pressure and Volume: Rapid Ejection

Cardiac Cycle

Pressure and Volume: Reduced Ejection

Cardiac Cycle

Pressure and Volume: Ventricle Relaxation

Cardiac Cycle

Phases

Cardiac Cycle

Electrocardiogram (ECG): Overview

Cardiac Cycle

Electrocardiogram (ECG): Diagnosis

Cardiac Cycle

Pressure and Volume: Atrial Contraction

Cardiac Cycle

Pressure and Volume: Isovolumetric Contraction

Introduction

Normal Values

Hemostasis

Disorders of Hemostasis: Thromboembolic Conditions

Hemostasis

Vascular Spasms

Hemostasis

Platelet Plug Formation

Hemostasis

Activated Platelets

Atherothrombosis

Superficial Plaque Erosion

Atherothrombosis

Platelets and Arterial Thrombosis

Platelet Receptor Physiology

Substances That Cause Platelet Aggregation

Platelet Receptor Physiology

Activation Pathways

Platelet Receptor Physiology

Thrombin

Measures of Platelet Aggregation

VerifyNow: P2Y12 Cartridge

Measures of Platelet Aggregation

Summary: Platelets

Measures of Platelet Aggregation

Light Transmission Aggregometry: Aggregometer

Measures of Platelet Aggregation

Light Transmission Aggregometry: Residual Aggregation

Measures of Platelet Aggregation

Other Methods of Assessing Platelet Aggregation

Introduction

Introduction: Thienopyridines

Clopidogrel Clinical Trials

High Loading Dose Studies

Clopidogrel Clinical Trials

CAPRIE

Introduction

Introduction: Acute Coronary Syndrome

Pathophysiology of Atherothrombosis: Overview

Pathophysiology of Atherothrombosis: Overview

Pathophysiology of Atherothrombosis: Overview

Atherogenesis

Pathophysiology of Atherothrombosis: Overview

Thrombus Formation

Acute Coronary Syndrome (ACS): Overview

Acute Coronary Syndrome (ACS): Overview

Acute Coronary Syndrome (ACS): Overview

Presentations of UA/NSTEMI

Acute Coronary Syndrome (ACS): Overview

STEMI

ACC/AHA Treatment Guidelines for ACS: Statistics

Recognition of Symptoms by Patient

ACC/AHA Treatment Guidelines for ACS: Statistics

Diagnosis by Clinician: Management of Patients

Drug Therapy in ACS: Overview

UA/NSTEMI: Anti-Ischemic Therapy

Drug Therapy in ACS: Overview

Nitrates

Drug Therapy in ACS: Overview

Beta Adrenergic Blockers

Drug Therapy in ACS: Overview

Calcium Channel Blockers

Drug Therapy in ACS: Overview

UA/NSTEMI: Antiplatelet Therapy

Drug Therapy in ACS: Overview

UA/NSTEMI: Anticoagulants

Drug Therapy in ACS: Overview

Low-Molecular-Weight Heparins (LMWHs)

Drug Therapy in ACS: Overview

Direct Thrombin Inhibitors

Drug Therapy in ACS: Overview

Factor Xa Inhibitors

Drug Therapy in ACS: Overview

Long-Term Anticoagulation (Warfarin/Coumarin)

Drug Therapy in ACS: Overview

STEMI: Anti-Ischemic Therapy Beta Blockers

Bleeding in ACS: Clinical Definition of Bleeding

Challenges

Bleeding in ACS: Clinical Definition of Bleeding

Need for Standardization of Bleeding Definition

Bleeding in ACS: Clinical Definition of Bleeding

Bleeding Risk

Bleeding in ACS: Clinical Definition of Bleeding

Minimizing Bleeding

Introduction: Interventional Cardiology

Cardiac Catheterization

Introduction: Interventional Cardiology

Stents

Introduction: Interventional Cardiology

Coronary Artery Bypass Graft (CABG) Surgery

Percutaneous Coronary Intervention (PCI)

PCI Aftercare

Intracoronary Stents

Balloon Angioplasty and Intracoronary Stent Placement: Left Anterior Descending Coronary Artery

Intracoronary Stents

Balloon Angioplasty and Intracoronary Stent Placement: Angiography After Balloon Dilatation of LAD

Intracoronary Stents

Adjunctive Drug Therapy

Stent Thrombosis

Definitions: Protocol Definitions and Limitations

Stent Thrombosis

Definitions: Protocol Definitions and Potential Bias

Stent Thrombosis

Mechanisms for Stent Thrombosis

Stent Thrombosis

Late Stent Thrombosis

Stent Thrombosis

Duration of Dual Antiplatelet Therapy: BASKET-LATE Trial

Stent Thrombosis

Long-Term Comparison of BMS and DES: Late Stent Thrombosis

Prasugrel Clinical Trials

Recurrent Events Data: Results and Conclusion

Vascular Anatomy

Interactivity: Vascular Anatomy

Role of the Heart and Circulatory System

Appearance: Pericardium

Role of the Heart and Circulatory System

The Heart is a Double Pump

Role of the Heart and Circulatory System

Role of Circulation

Anatomy of the Heart

Summary: Chambers of the Heart

Anatomy of the Heart

Overview: Anatomy of the Heart

Anatomy of the Heart

Summary: Coronary Arteries

Cardiac Cycle

Cardiac Cycle

Cardiac Cycle

Cardiac Muscle

Cardiac Cycle

Cardiac Output

Cardiac Cycle

Ejection Fraction

Cardiac Conduction

Cardiac Conduction System

Cardiac Conduction

Conduction: Sinus Node

Cardiac Conduction

Conduction: AV Node

Cardiac Conduction

His-Purkinje System

Blood

Plasma

Blood

Blood Composition

Patient Types and Risk Factors for Bleeding

Hemostasis and Bleeding Disorders

Patient Types and Risk Factors for Bleeding

Bleeding Disorders and Hypercoagulable States

Atrial Fibrillation (AF)

Atrial Fibrillation (AF) Definition

Causes of Atrial Fibrillation (AF), Associated Conditions

Atrial Fibrillation Without Associated Heart Disease

Pathophysiology of Atrial Fibrillation (AF)

Myocardial and Hemodynamic Consequences

Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) Diagnosis and Treatment Guidelines

DVT and PE Diagnosis Guidelines: Institute for Clinical Systems Improvement (ICSI)

Venous Thromboembolism (VTE) Prevention Guidelines

Venous Thromboembolism (VTE) Primary Prophylaxis

Complications of Atrial Fibrillation (AF)

Risk Stratification: CHADS2

CABG- Introduction and Overview

CABG- Introduction and Overview

Anatomy and Physiology

Mechanism of MI from CAD

Goals of Male Hypogonadism Replacement Therapy

Goals of Treatment for Male Hypogonadism

Blood Vessels

Major Circulatory Systems
Types of Blood Vessels
Structure and Function
Structure and...

Management of Patients with Atrial Fibrillation

Overview of Strategies and Rate Control

Aspirin and Primary Stroke Prevention

Aspirin and Primary Stroke Prevention: Recommendations

Pathophysiology of Atrial Fibrillation

Triggers and Mechanisms of Atrial Fibrillation

Epidemiology and Risk Factors

Proatherogenic Risk Factors

Overview of DVT and PE Diagnosis and Treatment

VTE Diagnosis: Clinical Methods

Overview of DVT and PE Diagnosis and Treatment

DVT and PE Diagnosis and Treatment Guidelines

VTE Prevention Guidelines

VTE Prevention in Medical Patients

Economic Burden of AF

Kim and Associates Study: The Annual Projected National Incremental Cost of AF

Cholesterol Metabolism, Lipoproteins, and Residual Risk: Introduction

Cholesterol Metabolism, Lipoproteins, and Residual Risk: Introduction

PCSK9 Inhibitors

Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)

Management of Patients with Atrial Fibrillation

Rhythm Control: Nonpharmacological Methods

Epidemiology and Natural History

Clinical Manifestations: Physical

Clopidogrel Clinical Trials

PCI Studies

Blood Vessels

Structure and Function: Tunica Intima

Cardiac Cycle

Pressure and Volume: Reduced Ventricular Filling

Cardiac Cycle

Electrocardiogram (ECG): Measurements

Atherothrombosis

High-Risk Atherothrombotic Plaque

Measures of Platelet Aggregation

VerifyNow: PRU: P2Y12 Reaction Units

Measures of Platelet Aggregation

Measure of Platelet Biomarkers VASP

Measures of Platelet Aggregation

Light Transmission Aggregometry: Tracing

Clopidogrel Clinical Trials

Registration Studies

Role of the Heart and Circulatory System

Summary: Functions of the Heart

Coronary Atherosclerosis: Overview

Inflammation and Atherosclerosis: ACS

Coronary Atherosclerosis: Overview

Inflammation and Atherosclerosis: Atherogenesis

Coronary Atherosclerosis: Overview

Inflammation and Atherosclerosis Inflammation, Plaque Rupture, and Thrombosis

Acute Coronary Syndrome (ACS): Overview

UA/NSTEMI

Drug Therapy in ACS: Overview

Facilitated PCI

Introduction: Interventional Cardiology

Cardiac Catheterization: Indications

Percutaneous Coronary Intervention (PCI)

Percutaneous Coronary Intervention (PCI): Overview

Percutaneous Coronary Intervention (PCI)

Percutaneous Coronary Intervention (PCI): Overview

Stent Thrombosis

Very Late and Cumulative Effects

Clopidogrel Clinical Trials

CHARISMA: Asymptomatic and Symptomatic

Anatomy of the Heart

Chambers: Right and Left Atrium, Right and Left Ventricles

Anatomy of the Heart

Coronary Veins

Cardiac Cycle

Fractional Shortening

Cardiac Cycle

Summary: Cardiac Cycle

Blood

Functions of Blood

Clot Formation

Coagulation and Hemostasis Overview

Overview of Bleeding Risk Schemes

ATRIA (AnTicoagulation and Risk factors In Atrial fibrillation)

Considerations in the Treatment of Bleeding

HASHTI and American Society of Hematology Definitions

Atrial Fibrillation (AF)

Normal Atrial Contraction and Electrocardiogram (ECG)

Atrial Fibrillation (AF)

Classification of Atrial Fibrillation (AF)

Causes of Atrial Fibrillation (AF), Associated Conditions

Familial Atrial Fibrillation
Obesity and Atrial Fibrillation

Pathophysiology of Atrial Fibrillation (AF)

Atrial Fibrillation (AF) Maintaining Mechanisms

Definition of Venous Thromboembolism (VTE)

Venous Thromboembolism (VTE) Overview

Definition of Venous Thromboembolism (VTE)

Hemodynamic Response to Pulmonary Embolism (PE)

Complications of Atrial Fibrillation (AF)

Virchow's Triad

Indications

Indications for CABG

Choice of Vessel Graft

Additional Factors Affecting the Choice of Vessel Graft

Total vs. Incomplete Revascularization

Total Revascularization

Anatomy and Physiology

Normal Coronary Circulation

Clinical Presentation and Diagnosis

Presentation

Clinical Presentation and Diagnosis

Knowledge Check: Clinical Presentation and Diagnosis

Clinical Management and Treatment

Management and Treatment

Male Reproductive Physiology

Testes
Testosterone

Dyslipidemia Disease State

Etiology

Insulin Resistance in Type 2 Diabetes Mellitus

Obesity and Dyslipidemia-associated Insulin Resistance

VTE Clinical Picture: Risk Factors and Comorbid States

Risk Factors and Comorbid States

Epidemiology

Risk Factors - Obesity

Rivaroxaban Clinical Trials: Atrial Fibrillation

ROCKET Atrial Fibrillation

Thromboembolic Complications

Risk of Thromboembolism

Management of Patients with Atrial Fibrillation

Rhythm Control and Preventing Thromboembolism

VTE Prevention Guidelines

(VTE) Prophylaxis: Patient-Related Thromboembolism Risk Factors

Rivaroxaban Clinical Trials: Acute Coronary Syndrome

ATLAS-ACS2 Trial

Economic Burden of AF

Kim and Associates Study: National Incremental Costs Incurred by Patients with AF

Comorbidities and Health-Related Quality of Life in Patients with AF

Comorbidities Commonly Associated with AF: Vascular Disease and CV Risk Factors

PCSK9 Inhibitors

Efficacy and Safety: Evolocumab

Fibrates

Side Effects, Efficacy, and Safety: Fibrates

Cardiac Cycle

Pressure and Volume: Isovolumetric Relaxation

Cardiac Cycle

Heart Sounds

Hemostasis

Coagulation: Phases

Hemostasis

Coagulation: Contact Activation Pathway

Introduction

Platelet Development Pathway
Platelets
Normal Values

Bleeding in ACS: Clinical Definition of Bleeding

Independent Predictors of Mortality

Introduction: Interventional Cardiology

Interventional Cardiology: Procedures

Intracoronary Stents

Drug-Eluting Stents (DES): Candidates for Drug-Eluting Stents

Stent Thrombosis

Stent Thrombosis: Overview

Clopidogrel Clinical Trials

MATCH Study

Role of the Heart and Circulatory System

Arteries, Veins, Capillaries

Anatomy of the Heart

Heart: Three Layers
Heart: Endocardium
Heart: Myocardium
Heart: Epicardium

Cardiac Conduction

Summary: Cardiac Conduction

Vascular Anatomy

Tunica Intima, Tunica Media, and Tunica Adventitia

Vascular Anatomy

Summary: Vascular Anatomy

Blood

Summary: Blood

Clot Formation

Platelet Adhesion, Activation, and Aggregation

Clinical Implications of Clot Formation

Thrombosis and Virchow's Triad

Overview of Bleeding Risk Schemes

Bleeding Risk Stratification Schemes: HEMORR2HAGES

Monitoring Patients at Risk of Thrombosis or Bleeding

Laboratory Tests and Complete Blood Count (CBC)

Considerations in the Treatment of Bleeding

Basic Management of Bleeding: Minor and Major Bleeding

Anticoagulant Reversal Agents

Factor VIII Inhibitor Bypass Activity (FEIBA)

Atrial Fibrillation (AF)

Related Arrythmias

AF Epidemiology

Epidemiology of Atrial Fibrillation (AF): Overview

AF Epidemiology

Prevalence of AF

Causes of Atrial Fibrillation (AF), Associated Conditions

Reversible Conditions

Venous Thromboembolism (VTE) Clinical Picture

Recurrent VTE and Mortality After Initial VTE

Venous Thromboembolism (VTE) Clinical Picture

Risk Factors for VTE and Classification

Venous Thromboembolism (VTE) Prevention Guidelines

Venous Thromboembolism (VTE) Primary Prophylaxis: Surgical and Non-Surgical Patients

Choice of Vessel Graft

Choice of Vessel Graft

Total vs. Incomplete Revascularization

CABG Techniques

Myocardial Infarction: Introduction and Overview

Myocardial Infarction: Introduction and Overview

Clinical Management and Treatment

NSTEMI and Special Groups

Clinical Management and Treatment

Stress-induced Cardiomyopathy (Takotsubo)

Prognosis

Short-term Prognosis Post-MI (STEMI and NSTEMI)

Clinical Prevention

Secondary Prevention

Statins

Efficacy and Safety: Secondary Prevention

Disease State

Common Complications

Impact of Diabetes

Proportion of Global Non-Communicable Disease Deaths Under the Age of 70 (2008)

Definition and Classification

Disease State, Spectrum of Disorders

Thromboembolic Complications

Risk of Thromboembolism: Risk Stratification

Thromboembolic Complications

Thromboembolic Complications: Atrial Stunning During Cardioversion

Overview: Venous Thromboembolism

Relationship between DVT and PE

Overview: Venous Thromboembolism

Impaired Gas Exchange During Pulmonary Embolism (PE) and Deep Vein Thrombosis (DVT)

VTE Clinical Picture: Risk Factors and Comorbid States

VTE Risk Factor Classification

VTE Clinical Picture: Natural History, Clinical Syndromes, Complications

Complications Associated with VTE

Overview of DVT and PE Diagnosis and Treatment

VTE Diagnosis

VTE Prevention Guidelines

Prevention in Surgical Patients

Apixaban Clinical Trials: Acute Coronary Syndrome

APPRAISE2 Trial

VTE Comorbidities and Health-Related Quality of Life

Risk Categories for VTE

Heart

Internal Anatomy

Stent Thrombosis

ARC Definitions

Anatomy of the Heart

Left and Right Coronary Arteries

Principles of Hemostasis

Coagulation Cascade: Intrinsic and Extrinsic Pathways, Thrombin Generation and Thrombin Functions

Monitoring Patients at Risk of Thrombosis or Bleeding

Overview, Signs and Symptoms of Bleeding

Monitoring Patients at Risk of Thrombosis or Bleeding

Other Laboratory Tests

Monitoring Patients at Risk of Thrombosis or Bleeding

Other Laboratory Tests: Activated Partial Thromboplastin Time and Thrombin Time

Monitoring Patients at Risk of Thrombosis or Bleeding

Other Laboratory Tests: Ecarin Clotting Time and Heptest

Anticoagulant Reversal Agents

Overview: Anticoagulant Reversal Agents and Vitamin K

Venous Thromboembolism (VTE) Clinical Picture

Complications Associated with VTE

Complications of Atrial Fibrillation (AF)

Risk of Thromboembolism

Complications of Atrial Fibrillation (AF)

Thromboembolic Complications: Impact of Stroke in Atrial Fibrillation

Choice of Vessel Graft

Venous Grafts

Choice of Vessel Graft

Techniques for Harvesting Arterial Grafts

Epidemiology

Epidemiology of Myocardial Infarction

Epidemiology

Risk Factors

Etiology

Etiology

Clinical Presentation and Diagnosis

Diagnosis, Misdiagnosis

Clinical Management and Treatment

STEMI

HAART-Associated Adverse Clinical Events

Elevated Lipids

Phase 3 Clinical Studies

Phase 3 Development Program

Epidemiology

Risk Factors - Other Factors

Treatment

Lifestyle Modification: Exercise and Physical Activity

Introduction to Monoclonal Antibodies

Antibodies as Therapy
Early Antibody Therapy: Polyclonal Antibodies
Hybridoma Technology: ...

Apixaban Clinical Trials: Venous Thromboembolism

AMPLIFY Study

Use of Novel Oral Anticoagulants

Venous Thromboembolism (VTE)

Epidemiology of Atrial Fibrillation

Epidemiology of Atrial Fibrillation: Overview

Causes of Atrial Fibrillation

Atrial Fibrillation Without Associated Heart Disease - Lone AF

Thromboembolic Complications

Transient Ischemic Attacks and Stroke and Impact of Stroke in Atrial Fibrillation

Overview: Venous Thromboembolism

VTE Epidemiology and Venous Thromboembolism (VTE) Location

VTE Prevention Guidelines

Risk Assessment, Effect of Anticoagulant Prophylaxis, and Thromboprophylaxis Recommendations

VTE Prevention Guidelines

Prevention in Surgical Patients or Orthopedic Surgery

Residual Risk

Definition of Residual Vascular Risk

Statins

Discovery of Statins

Emerging Therapies

Cholesteryl Ester Transfer Protein Inhibitors

Platelet Receptor Physiology

Substances That Cause Platelet Aggregation
Activation Pathways
ADP and Thromboxane A2

Vascular Anatomy

Major Arteries and Veins

Overview of Bleeding Risk Schemes

Bleeding Risk Schemes

Anticoagulant Reversal Agents

Protamine Sulfate, Platelets and Fresh Frozen Plasma (FFP)

Anticoagulant Reversal Agents

Prothrombin Complex Concentrates (PCC) and the Recombinant Factor VIIa (rFVIIa)

Atrial Fibrillation (AF)

Clinical Manifestations of AF

Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) Diagnosis and Treatment Guidelines

VTE Diagnosis Overview

Complications of Atrial Fibrillation (AF)

Risk Stratification: CHADS₂ Limitations

Use of Novel Oral Anticoagulants

Novel Oral Anticoagulants

Use of Novel Oral Anticoagulants

Venous Thromboembolism (VTE)

Technique: On-pump vs. Off-pump

Different Bypass Procedures

Clinical Presentation and Diagnosis

Diagnosis

Clinical Management and Treatment

STEMI: Reperfusion and Complications

Clinical Management and Treatment

NSTEMI

Biomarkers for the Diagnosis of AD

Plasma Biomarkers

Target Organ Damage

Target Organ Damage

Pharmacological Treatments

Selective Serotonin Reuptake Inhibitors (SSRIs)

Signs and Symptoms

Damage to Specific CNS Regions

Patient History

Presenting Symptoms in MS Patients

Epidemiology of Diabetes

Impact of Diabetes

Development of Monoclonal Antibodies

Safety Risks of Immune System Targeting

Psoriasis Therapies

Retinoids: Adverse Effects

What is the Role of Toxicology in Drug Development?

Safety Pharmacology

Potentially Modifiable Risk Factors

Metabolic Syndrome, Oxidative Stress and Inflammation

Potentially Modifiable Risk Factors

Hyperlipidemia and Diet

Mendelian Genetics

History of Cholesterol and Atherosclerosis

Glycemic Control Intervention in Type 2 Diabetes: ORIGIN

The Outcome Reduction with Initial Glargine INtervention trial (ORIGIN)

Phase III Data: ENGAGE AF-TIMI 48

ENGAGE AF-TIMI 48: Conclusions

Epidemiology

Incidence and Prevalence: International Diabetes Federation

Pathophysiology

Pathophysiology

Pathophysiology

Common Complications

VTE Clinical Picture: Risk Factors and Comorbid States

Risk Factors and Comorbid States

Management of Patients with Atrial Fibrillation

Rate and Rhythm Control

VTE Clinical Picture: Epidemiology

Incidence, Prevalence, Recurrent VE and Mortality After Initial VTE

Risk Factors for Atherosclerosis

Risk Factors and Atherosclerosis

AACE 2012 Guidelines for Management of Dyslipidemia and Prevention of Atherosclerosis

Treatment Recommendations

Heart

Functions: Blood Collection
Cardiac Myocytes: Sarcomeres and Myofibrils
Cardiac Myocytes: ...

Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) Diagnosis and Treatment Guidelines

VTE Diagnosis: Signs and Symptoms of PE

Treatment

Lifestyle Modification: Nutrition

Aspirin and Primary Stroke Prevention

Recommendations: Low Dose Aspirin

Comorbid Conditions

Comorbid Chronic Medical Conditions

Summary: Pathology of Diabetes Complications

Summary: Pathology of Diabetes Complications

Hypersensitivity

Type I Hypersensitivity Reaction: Immediate Hypersensitivity

Lifestyle Modifications and Prevention

Risk Factor Modification: Exercise and Healthy Diet

Diagnosis

Metabolic Syndrome Components: Abdominal Adiposity

Overview of Heart Failure

Heart Failure Diagnostic Criteria - Diagnostic Criteria

Association Between Atrial Fibrillation and Heart Failure

Pathophysiological Cycle

Treatment

Pharmacotherapy - Bile Acid Resins

Overview of Pulmonary Arterial Hypertension

Introduction: PAH

Treatment and Prevention of Cancer-associated VTE

Outpatients receiving chemotherapy: Preventive Therapy Trials

Treatment and Prevention of Cancer-associated VTE

Anticoagulant Treatment and Survival

Monoclonal Antibodies

Production of Monoclonal Antibodies by Hybridomas
Production of Monoclonal Antibodies in Mammal...

VTE Clinical Picture: Natural History, Clinical Syndromes, Complications

Natural History of VTE

Atherothrombosis

Overview: Atherothrombosis
Interactivity: Unstable Plaque
Interactivity: Thrombus Formatio...

Introduction to Monoclonal Antibodies

Naming Monoclonal Antibodies: Pali-vi-zu-mab

Patient History

Neurological History
Presenting Symptoms in MS Patients

The Nervous System

The CNS: Brain

Diagnosis of SLE

Standard Measures of Disease Activity Used in Clinical Trials: SLICC/ACR Damage Index for SLE

Diabetes Clinical Trials Studying Complications

DCCT/EDIC Study

Adult and Late-Onset Hypogonadism

Overview: Adult and Late-Onset Hypogonadism

Definition and Classification

History and Controversy: Syndrome X and WHO Definition

Epidemiology

Incidence and Prevalence: National Health and Nutrition Examination Survey

Epidemiology

Risk Factors - Genetic Predisposition

Pathophysiology

Retinopathy

Diagnosis

Metabolic Syndrome Components: Dyslipidemia and Blood Pressure

Overview of Heart Failure

Overview of Heart Failure (HF)

Overview of Heart Failure

Heart Failure Diagnostic Criteria - Signs and Symptoms

Diagnosis and Classification

Diagnosis and Classification

Management of Hypertension

Drug Combinations

Treatment

AACE Guidelines

Treatment

Pharmacotherapy - Cholesterol Absorption Inhibitor

Treatment

Pharmacotherapy - Niacin

Pathophysiologic Mechanisms

Pathophysiologic Mechanisms

Diagnosis and Prognosis

Diagnosis and Prognosis

Incidence and Risk of VTE in Cancer Patients

Risk Factors for Cancer-associated VTE

Risk Assessment, Diagnosis, and Prognosis of Cancer-associated VTE

Prognosis and Risk Factors of Cancer-associated VTE

Treatment and Prevention of Cancer-associated VTE

Outpatients receiving chemotherapy: Agnelli et al, 2009

Treatment and Prevention of Cancer-associated VTE

Prevention of VTE Recurrence

Summary: Binge Eating Disorder (BED) Disease State

Summary: Binge Eating Disorder (BED) Disease State

T2DM Diagnosis

Signs and Symptoms

Pathology of T2DM

Fat Cells: Increased FFAs, Excess Lipids

Management

Treatment Goals and Guidelines

Stroke Prevention Key Concepts

Summary: Stroke Prevention Key Concepts

Definition of Atrial Fibrillation

Atrial Fibrillation Definition

Thromboembolic Complications

Myocardial and Hemodynamic Consequences: Overview

Measures of Platelet Aggregation

Overview: Platelets
VerifyNow: Overview
VerifyNow: P2Y12 Cartridge
VerifyNow: PRU: P2...

Economic Burden of AF

Overview and Estimating Healthcare Costs Attributable to AF

Special Populations

NLA: Women

Epidemiology and Risk Factors

Risk Factors and Ischemic Stroke

Monoclonal Antibodies

Naming Monoclonal Antibodies

The Nervous System

The Central Nervous System (CNS)
The CNS: Brain

Introduction: Clinical Presentation of Lupus

Introduction: Clinical Presentation of Lupus

Diabetes Clinical Trial Design: Cohort Designs

Cohort Study

Microvascular Complications

Diabetic Neuropathy: Pathogenesis

Hypersensitivity

Type I Hypersensitivity Reaction: Immediate Hypersensitivity
Hypersensitivity Disorders: Type 1...

Diagnosis of Kidney Disease

Diagnosis: Patient History, Physical Examination and Urinalysis

Introduction to Kidney Disease

Diabetic Nephropathy (DN)

Disease State

Signs and Symptoms

Diabetic Nephropathy

Description: Diabetic Kidney Disease (DKD)

Overview: Angiogenesis

Functions of Angiogenesis

Phase III Data: ENGAGE AF-TIMI 48

Phase III Data: ENGAGE AF-TIMI 48: Study Overview

Pathophysiology

Nephropathy

Pathophysiology

Neuropathy

Diagnosis

Hyperglycemia and Diabetes

Overview of Heart Failure

Classification of Heart Failure: NYHA Functional Classification

Overview of Heart Failure

Heart Failure Diagnostic Criteria - Imaging

Overview of Heart Failure

Heart Failure Diagnostic Criteria - Laboratory Tests

Association Between Atrial Fibrillation and Heart Failure

Prognostic Significance of AF in Patients with HF

Definitions of Hypertension

Hypertension or High Blood Pressure

Disease State

Definition and Classification

Treatment

Pharmacotherapy - Fibrates

Treatment

Special Populations with Hyperlipidemia

Epidemiology and Risk Factors for PAH

Epidemiology and Risk Factors for PAH

Pathophysiologic Mechanisms

Overview of Vascular Smooth Muscle Cell Contraction

Diagnosis and Prognosis

Confirmation with Complete Right Heart Catheterization

Diagnosis and Prognosis

Natural History

Therapy

Therapy and Goals of Treatment

Therapy

Combination Therapy

Overview: Cancer VTE

VTE and Cancer

Incidence and Risk of VTE in Cancer Patients

Assessing Impact of Treatment on VTE Risk From Observational vs. Randomized Controlled Studies

Risk Assessment, Diagnosis, and Prognosis of Cancer-associated VTE

Diagnosis of Cancer-associated VTE: Wells Score

Treatment and Prevention of Cancer-associated VTE

VTE Therapeutic Agents

Summary: Cancer-associated VTE

Summary: Cancer-associated VTE

Epidemiology and Natural History

Natural History

Anxiety Disorders Disease: Introduction

Prevalence of Anxiety Disorders

Impact of Diabetes

Deaths Attributable to Disease
4 Out of 5 People with Diabetes Live in Low and Middle Income Co...

Resource Use and Costs Associated with Switching Warfarin in AF Patients

Antithrombotic Therapy for Atrial Fibrillation, Switching Warfarin Formulations, Kwong et al., 2012

Special Populations

NLA: South Asians

Special Populations

NLA: American Indians/Alaska Natives

Cardiac Cycle

Overview
Pressure and Volume: Rapid Ejection
Pressure and Volume: Reduced Ejection
Pr...

Effects of Vascular Injury

Blood Clot Formation

Phase I Data: Drug-Drug Interaction Data

Drug-Drug Interactions: Overview

Diagnosis of SLE

Standard Measures of Disease Activity Used in Clinical Trials: SLEDAI-2K
Standard Measures of D...

Epidemiology of Diabetes

Impact of Diabetes
Effect of Type 2 Diabetes and Obesity on Quality of Life Score
Diabetic...

Introduction: Pathology of Diabetes Complications

Chronic Diabetes Complications: Macrovascular and Diabetic Foot

Psoriasis Therapies

Systemic Therapies: Retinoids
Retinoids: Mechanism of Action
Retinoids: Clinical Efficacy

What is the Role of Toxicology in Drug Development?

How Does Toxicology Relate to the Pre-Clinical Road Map?
Safety Pharmacology
In Vivo and I...

Diabetic Nephropathy

Kidney Disease Treatment: Goals and Components

Basal Insulin: Degludec

Basal Insulin Analog: Insulin Degludec

Definition and Classification

Spectrum of Disorders

Definition and Classification

History and Controversy: Harmonizing the Metabolic Syndrome

Therapeutic Considerations

Other Pharmacologic Therapy

Resistant Hypertension

Types of Hypertension

Disease State

Basic Lipid Biochemistry

Disease State

Etiology of Hyperlipidemia

Epidemiology

Epidemiology, Incidence and Prevalence

Diagnosis and Monitoring

Diagnostic Tests

Pathophysiologic Mechanisms

Overview of Blood Vessel Architecture

Therapy

Pathway-Specific Approaches

Overview: Cancer VTE

Venous Thromboembolism (VTE) Overview

Incidence and Risk of Cancer in VTE Patients

Incidence of Cancer in VTE Patients

Incidence and Risk of VTE in Cancer Patients

Incidence of VTE in Cancer Patients

Incidence and Risk of VTE in Cancer Patients

Cancer-related Risk Factors

Incidence and Risk of VTE in Cancer Patients

Mechanisms Underlying Cancer-associated VTE

Risk Assessment, Diagnosis, and Prognosis of Cancer-associated VTE

Risk Assessment Tools

Treatment and Prevention of Cancer-associated VTE

Guidelines for VTE Prevention and Treatment

BED Disease State

Diagnostic Criteria, Disease Onset, and Clinical Course

Neurology/Major Depressive Disorder Disease: Introduction

Major Depressive Disorder (MDD)

Clinical Implications of Clot Formation

Thrombosis

Special Populations

NLA: African Americans

Monoclonal Antibodies

Monoclonal Antibody Production
Monoclonal Antibody Production: Knowledge Check

Development of Monoclonal Antibodies

Monoclonal Antibody Production in Hybridomas
Monoclonal Antibody Production in CHO Cells
M...

Clinical Trials Comparing GLP-1 Receptor Agonists

Comparison of GLP-1 Receptor Agonists

HAART-Associated Adverse Clinical Events

HAART-Associated Adverse Clinical Events
Lactic Acidosis
Liver Toxicity
Glucose Intol...

Osteoporosis and Obesity

Background

Measures of Kidney Function

Blood Urea Nitrogen (BUN), Urine Protein, and Possible Causes of Proteinurina

Phase III Data: Hokusai-VTE

Methods: Patient Population

Overview of Heart Failure

Classification of Heart Failure: Conventional Classification

Epidemiology of Heart Failure

Risk Factors for HF

Therapeutic Considerations

Therapeutic Considerations: Overview

Epidemiology

Epidemiology

Causes of Secondary Hypertension

Causes of Secondary Hypertension

Management of Hypertension

Hypertension Management Guidelines

Treatment

Pharmacotherapy - Statins

Epidemiology and Risk Factors

Epidemiology

Epidemiology and Risk Factors for PAH

Risk Factors

Pathophysiologic Mechanisms

Specific Mediators

Effects of Opioids

Effects of Opioids

Management

Goals of Treatment

Special Populations

Special Populations: Introduction

Systemic Therapy

Systemic Therapy: Purpose

Monoclonal Antibodies

Monoclonal Antibody Production

Glycemic Endpoint Studies

Dulaglutide Glycemic Endpoint Trials: Umpierrez et al. EGO Study

Atopy vs. Allergy

Hypersensitivity Disorders

Association Between Atrial Fibrillation and Heart Failure

AF and HF: Overview

Etiology of Hypertension

Risk Factors

Pathophysiology

Pathophysiology

Overview of Pulmonary Arterial Hypertension

Overview of Pulmonary Arterial Hypertension

Diagnosis and Prognosis

Pivotal Tests

Annotate: Hokusai

Hokusai-VTE Trial

Pathology of T2DM

Insulin Resistance: Hepatic (Liver)
Decreased Glucose Uptake (Muscle)
Decreased Insulin Se...

Guidelines for Anticoagulant Therapy

Atrial Fibrillation (AF): Stroke Risk

Clopidogrel Clinical Trials

CAPRIE: Conclusion

Clopidogrel Clinical Trials

COMMIT Study

Plavix® vs. Effient™

Variability of Response: IPA Link to Clinical Outcomes

Hypersensitivity

Type IV Hypersensitivity Reaction Subgroups
Gell-Coombs Classification
Type I Hypersensiti...

Epidemiology of Heart Failure

Epidemiology of HF: Overview

Management of Hypertension in Special Populations

Management of Hypertension in Special Populations

Management of Hypertension

Medications

Diagnosis

Physical Examination: Other

Annotate: ENGAGE

Edoxaban versus Warfarin in Patients with Atrial Fibrillation

Diabetes Annotations

Jardiance

Clopidogrel Clinical Trials

CLARITY Study

Thienopyridines

Approved Indications

Psoriatic Arthritis Therapies

Symptomatic Treatment
Symptomatic Treatment: Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)

Psoriatic Arthritis Therapies

Symptomatic Treatment: Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)

NSAIDs

Introduction: NSAIDs

Diabetes Annotations

Abasaglar insulin glargine

Standard Agents: Therapeutic Challenges

Unfractionated Heparin: Warnings and Precautions

Physical Exam

Physical Examination: Other

SLE Treatments: NSAIDs

Main Types of NSAIDs

SLE Treatments: NSAIDs

Main Types of NSAIDs
Mode of Action
Indicated for Use in SLE

Diabetes Annotations

AWARD-2 Study

Kidney Function: GFR

Measure of Kidney Function

Macrovascular Complications

Chronic Diabetes Complications: Macrovascular

Signs and Symptoms

Damage to Specific CNS Regions

Epidemiology

Mortality and Survival

Adult and Late-Onset Hypogonadism

Comorbidities: Overview

Mendelian Genetics

Mendelian Genetics and History of Cholesterol and Atherosclerosis

Combination Product Regulation

Combination Products: Approval as Drug or Device

Signs and Symptoms

Signs and Symptoms Overview: Impact on the Patient
Damage to Specific CNS Regions
Damage t...

Monitoring

Compliance Toxicities
Patient Compliance
Toxicity

Monitoring

Toxicity

Clinical Trials: Event Definitions

Analyzing the Results of Diabetes Trials: Relative Risk

Infliximab

Pivotal Trials: Efficacy of Maintenance
Infliximab Safety

Infliximab

Infliximab Safety

Aspirin and Primary Stroke Prevention

Clinical Trials and Meta-analysis Data

Epidemiology

Longitudinal Studies: Age-Associated Diseases

Overview of Obesity

Health Consequences of Overweight and Obesity

Diagnosis

History: Presenting Symptoms in MS Patients

Health Outcomes

Dulaglutide: AWARD-1 Reaney M., et al., 2013

Management

Goals of Treatment

Overview of Obesity

Overweight/Obese Defined
Body Mass Index
Waist Circumference and Obesity
Cause of Obe...

Current Therapies

Symptomatic Therapies

SLE Treatments: MAbs/Biologics

Belimumab Clinical Trials 2 and 3: Efficacy
Belimumab Clinical Trials 2 and 3: Warnings and Pre...

SLE Treatments: MAbs/Biologics

Belimumab Clinical Trials 2 and 3: Warnings and Precautions

Complications of RA

Major Organs Affected by RA

T1DM (Type 1 Diabetes)

Incidence of T1DM Varies with Race

Diagnosis

Overview: The Challenge of Diagnosis
Physical Examination: Motor
Physical Examination: Oth...

Steroids

Glucocorticoids: Mode of Action
The Anti-Inflammatory Effects of Corticosteroids
Glucocort...

Steroids

Glucocorticoids: Side Effects

Typical Course of Plaque Psoriasis

Onset, Episodes, Flare-Ups, Triggers
Complications and Comorbidities of Psoriasis

Typical Course of Plaque Psoriasis

Complications and Comorbidities of Psoriasis

Emerging Hypotheses on Treatment

Immunological Concepts: Oral Immune-Modulating Drugs

Criteria for the Diagnosis of Dementia Due to Alzheimer's Disease

Differential Diagnosis

Visualization

Acute Ischemic Stroke: Thrombolysis

Background

Tissue Plasminogen Activator (tPA)

Visualization: The NINDS Study

NINDS Study

Stroke: NIHSS Criteria

Cohort Studies: Background
Modified Rankin Score
NIHSS Criteria

Stroke: NIHSS Criteria

Cohort Studies: Background

Stroke: NIHSS Criteria

Modified Rankin Score

Stroke: NIHSS Criteria

NIHSS Criteria

Background

Clinical Trials

Background

Thrombolytic Therapy

Stroke Outcome Measures

Barthel Index
Modified Rankin Score
Glasgow Outcome Scale
NIHSS Criteria

Stroke Outcome Measures

Barthel Index

Stroke Outcome Measures

Modified Rankin Score

Stroke Outcome Measures

Glasgow Outcome Scale

Stroke Outcome Measures

NIHSS Criteria

Background

Penumbra

Rationale For Use of Novel Oral Anticoagulants

Overview of Anticoagulant Agents

Rationale For Use of Novel Oral Anticoagulants

Limitations of Traditional Rapid Acting and Oral Anticoagulants

Rationale For Use of Novel Oral Anticoagulants

Development, Advantages and Limitations of Novel Oral Anticoagulants

Rationale For Use of Novel Oral Anticoagulants

Use of Anticoagulants and FDA Approved Novel Oral Anticoagulants

Use of Novel Oral Anticoagulants

Stroke Prevention in Atrial Fibrillation

Use of Novel Oral Anticoagulants

Acute Coronary Syndrome (ACS)

Use of Novel Oral Anticoagulants: Overview

Use of Novel Oral Anticoagulants: Overview

Novel Oral Anticoagulant (NOAC) Targets

Novel Oral Anticoagulants: Direct Thrombin Inhibitors - Dabigatran

Dabigatran: Overview, Indications, Dosage and Administration

Introduction: Hemostasis and Bleeding Management

Introduction: Hemostasis and Bleeding Management

Introduction

Clot Formation

Clot Formation: Coagulation

Clinical Implications of Clot Formation

Arterial Thrombosis

Clinical Implications of Clot Formation

Atrial Fibrillation and Venous Thrombosis

Patient Types and Risk Factors for Bleeding

Bleeding Disorders

Bleeding Risk Stratification

Bleeding Risk Schemes: Overview

Bleeding Risk Stratification

Bleeding Risk Stratification Schemes

Laboratory Monitoring of Patients at Risk of Thrombosis or Bleeding

Overview: Complete Blood Count, Fecal Occult Blood Test and Other Laboratory Tests

Laboratory Monitoring of Patients at Risk of Thrombosis or Bleeding

Laboratory Tests of Patients at Risk of Thrombosis or Bleeding

Patient Education

Patient Involvement, Compliance and Education

Treatment of Bleeding

Overview: Basic Management of Bleeding

Anticoagulant Reversal

Overview: Anticoagulant Reversal Agents

Anticoagulant Reversal

Factor VIII Inhibitor Bypass Activity (FEIBA)

Standard Agents: Therapeutic Challenges

Enoxaparin: Contraindications and Dalteparin: Warnings and Precautions

Introduction

Introduction

Introduction

Introduction

Guidelines for Prophylactic Anticoagulant Therapy

Prevention in Surgical Patients Non-Orthopedic Surgery: American College of Chest Physicians (ACCP) ...

Guidelines for Prophylactic Anticoagulant Therapy

Prevention in Surgical Patients Non-Orthopedic Surgery

Guidelines for Prophylactic Anticoagulant Therapy

Prevention in Surgical Patients and Orthopedic Surgery

Guidelines for Prophylactic Anticoagulant Therapy

VTE Prevention in Medical Patients: Increased Risk for VTE

Introduction

Introduction

Guidelines for Prophylactic Anticoagulant Therapy

Overview of Anticoagulation Therapy

Guidelines for Prophylactic Anticoagulant Therapy

Atrial Fibrillation Overview

Guidelines for Prophylactic Anticoagulant Therapy

Atrial Fibrillation Stroke Risk

Guidelines for Prophylactic Anticoagulant Therapy

Risk of Thromboembolism

Guidelines for Prophylactic Anticoagulant Therapy

Guidelines for Anticoagulation Therapy

Guidelines for Prophylactic Anticoagulant Therapy

Venous Thromboembolism (VTE) Prophylaxis

Guidelines for Prophylactic Anticoagulant Therapy

VTE Prevention in Medical Patients

Guidelines for Prophylactic Anticoagulant Therapy

ACCP, AAOS, ASRA Compendium of Consensus Recommendations for VTE Prophylaxis

Guidelines for Prophylactic Anticoagulant Therapy

Prevention in Surgical Patients and Orthopedic Surgery: American College of Chest Physicians Guideli...

Guidelines for Anticoagulant Venous Thromboembolism Therapy

Venous Thromboembolism Overview

Guidelines for Anticoagulant Venous Thromboembolism Therapy

Pulmonary Embolism

Guidelines for Anticoagulant Venous Thromboembolism Therapy

Pulmonary Embolism Treatment

Guidelines for Anticoagulant Venous Thromboembolism Therapy

Venous Thromboembolism Treatment

Guidelines for Anticoagulant Venous Thromboembolism Therapy

Venous Thromboembolism Treatment: Uncomplicated Initial Treatment

Guidelines for Anticoagulant Venous Thromboembolism Therapy

Venous Thromboembolism Treatment: Complications or Comorbidities

Guidelines for Anticoagulant Venous Thromboembolism Therapy

Venous Thromboembolism Treatment: Complications During Therapy

Guidelines for Anticoagulant Venous Thromboembolism Therapy

Venous Thromboembolism Treatment: ACCP Treatment Guidelines

Guidelines for Anticoagulant Venous Thromboembolism Therapy

Follow-Up and Secondary Prevention - Duration of Treatment

Guidelines for Anticoagulant Venous Thromboembolism Therapy

Follow-Up and Secondary Prevention: Bridging and Perioperative Management

Guidelines for Anticoagulant Venous Thromboembolism Therapy

Follow-Up and Secondary Prevention - Chronic Thromboembolic Pulmonary Hypertension

Standard Agents: Overview

Standard Anticoagulants

Standard Agents: Overview

Vitamin K Antagonists (VKAs)

Standard Agents: Overview

Aspirin: Overview

Standard Agents: Overview

Aspirin: Mechanism of Action

Standard Agents: Overview

Unfractionated Heparin: Overview

Standard Agents: Overview

Low-Molecular-Weight Heparin (LMWH)

Standard Agents: Overview

Low-Molecular-Weight Heparin (LMWH): Dosage and Administration

Standard Agents: Overview

Fondaparinux: Overview

Standard Agents: Clinical Studies

Standard Agents: Clinical Studies

Vitamin K Antagonists (VKAs): Warfarin

Standard Agents: Clinical Studies

Vitamin K Antagonists (VKAs) Warfarin: Acute Venous Thromboembolism (VTE)

Standard Agents: Clinical Studies

Vitamin K Antagonists (VKAs) Warfarin: ACCP CHEST Guidelines

Standard Agents: Overview

Vitamin K Antagonists (VKAs) Warfarin: Venous Thromboembolism (VTE)

Standard Agents: Clinical Studies

Aspirin

Standard Agents: Clinical Studies

Unfractionated Heparin (UFH) and Low-Molecular-Weight Heparins (LMWHs)

Standard Agents: Clinical Studies

Recurrent Venous Thromboembolism (VTE)

Standard Agents: Clinical Studies

Fondaparinux: Clinical Studies

Standard Agents: Therapeutic Challenges

Therapeutic Challenges of Antithrombotic Treatment

Standard Agents: Therapeutic Challenges

Vitamin K Antagonists (VKAs): Warfarin Contraindications

Standard Agents: Therapeutic Challenges

Vitamin K Antagonists (VKAs): Warfarin Special Considerations and Drug Interactions

Standard Agents: Therapeutic Challenges

Vitamin K Antagonists (VKAs): Warfarin Monitoring and Warfarin Anticoagulant Reversal

Standard Agents: Therapeutic Challenges

Aspirin: Warnings and Precautions

Standard Agents: Therapeutic Challenges

Aspirin: Anticoagulant Reversal

Standard Agents: Therapeutic Challenges

Unfractionated Heparin: Contraindications, Monitoring and Anticoagulation Reversal

Standard Agents: Therapeutic Challenges

Enoxaparin and Dalteparin: Boxed Warning

Standard Agents: Therapeutic Challenges

Enoxaparin: Warnings and Precautions

Standard Agents: Therapeutic Challenges

Dalteparin Contraindications and Laboratory Monitoring

Standard Agents: Therapeutic Challenges

Fondaparinux: Boxed Warning

Standard Agents: Therapeutic Challenges

Fondaparinux: Warnings and Precautions

Standard Agents: Therapeutic Challenges

Fondaparinux: Contraindications, Laboratory Monitoring and Anticoagulant Reversal

Table of Agents for Review

Table of Agents for Review

Novel Oral Anticoagulants: Direct Thrombin Inhibitors - Dabigatran

Direct Thrombin Inhibitors: Mechanism of Action and Clinical Pharmacology

Novel Oral Anticoagulants: Direct Thrombin Inhibitors - Dabigatran

Dabigatran: Special Considerations

Novel Oral Anticoagulants: Direct Thrombin Inhibitors - Dabigatran

Dabigatran: Contraindications, Warnings and Precautions

Novel Oral Anticoagulants: Direct Thrombin Inhibitors - Dabigatran

Dabigatran: Use in Pregnancy, Laboratory Monitoring and Anticoagulant Reversal

Novel Oral Anticoagulants: Factor Xa Inhibitors - Rivaroxaban

Rivaroxaban: Overview, Indications, Dosage and Administration

Novel Oral Anticoagulants: Factor Xa Inhibitors - Rivaroxaban

Rivaroxaban: Mechanism of Action and Clinical Pharmacology

Novel Oral Anticoagulants: Factor Xa Inhibitors - Rivaroxaban

Rivaroxaban: Special Considerations, Contraindications and Boxed Warning

Novel Oral Anticoagulants: Factor Xa Inhibitors - Rivaroxaban

Rivaroxaban: Warnings and Precautions

Novel Oral Anticoagulants: Factor Xa Inhibitors - Rivaroxaban

Rivaroxaban: Use in Pregnancy, Laboratory Monitoring and Anticoagulant Reversal

Novel Oral Anticoagulants: Factor Xa Inhibitors - Apixaban

Apixaban: Overview, Dosage and Administration

Novel Oral Anticoagulants: Factor Xa Inhibitors - Apixaban

Apixaban: Mechanism of Action and Clinical Pharmacology

Novel Oral Anticoagulants: Factor Xa Inhibitors - Apixaban

Apixaban: Special Considerations

Novel Oral Anticoagulants: Factor Xa Inhibitors - Apixaban

Apixaban: Contraindications and Boxed Warning

Novel Oral Anticoagulants: Factor Xa Inhibitors - Apixaban

Apixaban: Warning and Precautions

Novel Oral Anticoagulants: Factor Xa Inhibitors - Apixaban

Apixaban: Use in Pregnancy, Laboratory Monitoring and Anticoagulant Reversal

Novel Oral Anticoagulants: Factor Xa Inhibitors

Emerging Factor Xa Inhibitors: Edoxaban and Betrixaban

Summary of Agents

Table of Agents for Review

Learning Objectives

Learning Objectives

Dabigatran Clinical Trials: Atrial Fibrillation

Dabigatran Clinical Trials

Dabigatran Clinical Trials: Atrial Fibrillation

RELY Study

Dabigatran Clinical Trials: Atrial Fibrillation

RELY: Study Population Results

Dabigatran Clinical Trials: Atrial Fibrillation

RELY Results: Primary Outcome Stroke or Systemic Embolism

Dabigatran Clinical Trials: Atrial Fibrillation

RELY Results: Secondary Outcome Stroke

Dabigatran Clinical Trials: Atrial Fibrillation

RELY Results: Other Outcomes

Dabigatran Clinical Trials: Atrial Fibrillation

RELY Results: Primary Safety Outcome Major-Bleeding, Dabigatran vs. Warfarin

Dabigatran Clinical Trials: Atrial Fibrillation

RELY-ABLE

Dabigatran Clinical Trials: Atrial Fibrillation

RELY-ABLE Trial

Dabigatran Clinical Trials: Venous Thromboembolism

RECOVER Trial

Dabigatran Clinical Trials: Venous Thromboembolism

RECOVER: Study Population Results

Dabigatran Clinical Trials: Venous Thromboembolism

RECOVER: Primary and Secondary Efficacy Results

Dabigatran Clinical Trials: Venous Thromboembolism

RECOVER: Results Summary

Dabigatran Clinical Trials: Venous Thromboembolism

REMEDY and RESONATE Trials

Dabigatran Clinical Trials: Acute Coronary Syndrome

REDEEM Trial

Dabigatran Clinical Trials: Acute Coronary Syndrome

REDEEM Trial: D-dimer Concentrations

Dabigatran Clinical Trials: Acute Coronary Syndrome

Development Programs: RE-ALIGN Heart Valves

Dabigatran Clinical Trials: Summary

Dabigatran Clinical Trials: Summary

Rivaroxaban Clinical Trials: Atrial Fibrillation

Rivaroxaban Clinical Trials: Overview

Rivaroxaban Clinical Trials: Atrial Fibrillation

ROCKET Atrial Fibrillation: Baseline Characteristics Results

Rivaroxaban Clinical Trials: Atrial Fibrillation

ROCKET Atrial Fibrillation: Primary Efficacy Results

Rivaroxaban Clinical Trials: Atrial Fibrillation

ROCKET Atrial Fibrillation: Primary Efficacy Events During Transition to Open-Label Therapy

Rivaroxaban Clinical Trials: Atrial Fibrillation

ROCKET Atrial Fibrillation: Secondary Efficacy Outcomes

Rivaroxaban Clinical Trials: Atrial Fibrillation

ROCKET Atrial Fibrillation: Results Summary

Rivaroxaban Clinical Trials: Atrial Fibrillation

XANTUS Study

Rivaroxaban Clinical Trials: Venous Thromboembolism

EINSTEIN-DVT Study

Rivaroxaban Clinical Trials: Venous Thromboembolism

EINSTEIN-DVT: Baseline Characteristic Results

Rivaroxaban Clinical Trials: Venous Thromboembolism

EINSTEIN-DVT: Primary Efficacy Results

Rivaroxaban Clinical Trials: Venous Thromboembolism

EINSTEIN-DVT: Primary Efficacy Results Time Course

Rivaroxaban Clinical Trials: Venous Thromboembolism

EINSTEIN-DVT: Safety Results

Rivaroxaban Clinical Trials: Venous Thromboembolism

EINSTEIN-DVT: Net Clinical Benefit and Summary

Rivaroxaban Clinical Trials: Venous Thromboembolism

EINSTEIN-PE Trial

Rivaroxaban Clinical Trials: Venous Thromboembolism

EINSTEIN-PE: Baseline Characteristics Results

Rivaroxaban Clinical Trials: Venous Thromboembolism

EINSTEIN-PE: Primary Efficacy Results

Rivaroxaban Clinical Trials: Venous Thromboembolism

EINSTEIN-PE: Primary Efficacy Results Time Course

Rivaroxaban Clinical Trials: Venous Thromboembolism

EINSTEIN-PE: Safety Results

Rivaroxaban Clinical Trials: Venous Thromboembolism

EINSTEIN-PE: Net Clinical Benefit and Summary

Rivaroxaban Clinical Trials: Venous Thromboembolism

EINSTEIN-EXT Study

Rivaroxaban Clinical Trials: Venous Thromboembolism

XALIA Study

Rivaroxaban Clinical Trials: Acute Coronary Syndrome

X-PLORER Study

Rivaroxaban Clinical Trials: Overview of Other Development Programs

Development Programs: Rivaroxaban

Rivaroxaban Clinical Trials: Summary

Rivaroxaban Clinical Trials: Summary

Apixaban Clinical Trials: Atrial Fibrillation

Apixaban Clinical Trials

Apixaban Clinical Trials: Atrial Fibrillation

AVERROES Study

Apixaban Clinical Trials: Atrial Fibrillation

ARISTOTLE Trial

Apixaban Clinical Trials: Atrial Fibrillation

ARISTOTLE: Baseline Characteristics Results

Apixaban Clinical Trials: Atrial Fibrillation

ARISTOTLE: Efficacy Results

Apixaban Clinical Trials: Atrial Fibrillation

ARISTOTLE: Safety Results

Apixaban Clinical Trials: Atrial Fibrillation

ARISTOTLE: Results Summary

Apixaban Clinical Trials: Venous Thromboembolism

AMPLIFY Study: Baseline Characteristics Results and Primary Efficacy Results

Apixaban Clinical Trials: Venous Thromboembolism

AMPLIFY Study: Safety Results

Apixaban Clinical Trials: Venous Thromboembolism

AMPLIFY Study: Results Summary

Apixaban Clinical Trials: Venous Thromboembolism

AMPLIFY-EXT Study

Apixaban Clinical Trials: Overview of Other Development Programs

Development Programs: Overview

Apixaban Clinical Trials: Summary

Apixaban Clinical Trials: Summary

Introduction

Introduction

Economic Burden of AF

Cost of AF from a Payer Perspective

Economic Burden of Stroke

Overview: Strokes in AF

Economic Burden of Stroke

Stroke Risk Based Upon Anticoagulation Use

Economic Burden of Stroke

Cost Based Upon Anticoagulation Use

Economic Burden of Bleeding

Overview: Antithrombotic Therapy for Atrial Fibrillation

Economic Burden of Bleeding

Mercaldi and Associates Study

Economic Burden of Bleeding

Per Patient Cost of Bleeding

Economic Burden of Bleeding

Ghate and Coworkers Analysis

Economic Burden of Bleeding

Summary of Costs for AF, Stroke and Bleeding

Comorbidities and Health-Related Quality of Life in Patients with AF

Comorbidities Commonly Associated with AF

Comorbidities and Health-Related Quality of Life in Patients with AF

Comorbidities Commonly Associated with AF: Wu et al., 1995

Comorbidities and Health-Related Quality of Life in Patients with AF

Health-Related Quality of Life (HRQoL) in AF Patients

Comorbidities and Health-Related Quality of Life in Patients with AF

Health-Related Quality of Life Studies in Atrial Fibrillation

Resource Use and Costs Associated with Switching Warfarin in AF Patients

Kwong and Associates Study

Resource Use and Costs Associated with Switching Warfarin in AF Patients

Methods Patient Population, Study Design and Endpoints

Resource Use and Costs Associated with Switching Warfarin in AF Patients

Results: Patient Population

Resource Use and Costs Associated with Switching Warfarin in AF Patients

Results: Health Care Resource Use Analysis

Resource Use and Costs Associated with Switching Warfarin in AF Patients

Results: Health Care Resource Use Analysis, Controlled for variables

Resource Use and Costs Associated with Switching Warfarin in AF Patients

Results: Health Care Cost Analysis - Unadjusted Costs

Resource Use and Costs Associated with Switching Warfarin in AF Patients

Results: Health Care Cost Analysis - Generic vs. Brand-Only

Resource Use and Costs Associated with Switching Warfarin in AF Patients

Conclusion: Use and Costs Associated with Switching Warfarin

Resource Use and Costs Associated with Switching Warfarin in AF Patients

Table Summary of Kwong et. al, 2012

Economic Burden of VTE

Overview of VTE

Economic Burden of VTE

Total Cost of VTE

Economic Burden of VTE

Per Patient Cost of DVT and PE

Economic Burden of VTE

Per Patient Cost of Recurrent VTE

Economic Burden of VTE

Incremental Cost of Recurrent VTE

Economic Burden of VTE

Summary of Costs for VTE

VTE Comorbidities and Health-Related Quality of Life

Overview and Incidence of VTE

VTE Comorbidities and Health-Related Quality of Life

VTE Prevalence Increases with Age

VTE Comorbidities and Health-Related Quality of Life

Projected VTE Prevalence Increases with Time

VTE Comorbidities and Health-Related Quality of Life

Comorbidities Commonly Associated with VTE

VTE Comorbidities and Health-Related Quality of Life

Risk Factors for VTE

VTE Comorbidities and Health-Related Quality of Life

Health-Related Quality of Life (HRQoL) in VTE Patients

VTE Comorbidities and Health-Related Quality of Life

Health-Related Quality of Life (HRQoL) in VTE Patients: Acute Deep Vein Thrombosis

VTE Comorbidities and Health-Related Quality of Life

Health-Related Quality of Life (HRQoL) in VTE Patients: Post-Thrombotic Syndrome

Cost-Effective Analyses Overview

Cost-Effective Analyses Overview

Cost-Effective Analyses Overview

Cost-Effective Analyses (CEAs)

Cost-Effectiveness Studies: Harrington et al., 2013

Harrington Study: Warfarin Compared to NOACs

Cost-Effectiveness Studies: Harrington et al., 2013

Study Overview: Harrington et al.

Cost-Effectiveness Studies: Harrington et al., 2013

Methods Patient Population

Cost-Effectiveness Studies: Harrington et al., 2013

Methods Study Design

Cost-Effectiveness Studies: Harrington et al., 2013

Methods Endpoints

Cost-Effectiveness Studies: Harrington et al., 2013

Harrington Study: Results

Cost-Effectiveness Studies: Harrington et al., 2013

Harrington Study: Conclusions

Cost-Effectiveness Studies: Kansal et al., 2013

Overview: Kansal Study

Cost-Effectiveness Studies: Kansal et al., 2013

Kansal Study: Study Overview

Cost-Effectiveness Studies: Kansal et al., 2013

Kansal Study: Methods and Literature Search Strategy

Cost-Effectiveness Studies: Kansal et al., 2013

Kansal Study: Results

Cost-Effectiveness Studies: Kansal et al., 2013

Results: Cost-Effectiveness of Factor Xa Inhibitors

Cost-Effectiveness Studies: Kansal et al., 2013

Kansal Study: Conclusions

Cost-Effectiveness Studies: Mahmoudi and Sobieraj, 2013

Mahmoudi and Sobieraj Study: Overview

Cost-Effectiveness Studies: Mahmoudi and Sobieraj, 2013

Mahmoudi and Sobieraj Study: Study Overview

Cost-Effectiveness Studies: Mahmoudi and Sobieraj, 2013

Methods: Cost-Effectiveness Model

Cost-Effectiveness Studies: Mahmoudi and Sobieraj, 2013

Methods: Studies Included in the Analysis and Quality-of-Life Measures

Cost-Effectiveness Studies: Mahmoudi and Sobieraj, 2013

Methods Endpoints: Costs

Cost-Effectiveness Studies: Mahmoudi and Sobieraj, 2013

Results: Base-Case Analysis and Conclusion

Cost-Effectiveness Studies: Mahmoudi and Sobieraj, 2013

Summary of Cost-Effectiveness Studies

Overview of the Pathophysiology of Arthrosclerosis/CVD: Introduction

Overview of the Pathophysiology of Arthrosclerosis

Overview of Atherothrombosis

Virchow's Triad

Overview of Atherothrombosis

Arterial Thrombosis

Pathogenesis of Atherogenesis

Atherogenesis

Pathogenesis of Atherogenesis

Involvement of Platelets

Risk Factors for CHD and MI

Risk Factors

Basic Lipid Biochemistry

Basic Lipid Biochemistry

Basic Lipid Biochemistry

Lipid Transport System

Basic Lipid Biochemistry

Cholesterol Regulation

Dyslipidemia Disease State

Definition and Classification of Dyslipidemia

Dyslipidemia Disease State

Etiology of Secondary Dyslipidemia

Epidemiology

Epidemiology

Treatment Options: Introduction and Overview

Treatment Options: Introduction and Overview

Treatment Options: Learning Objectives

Treatment Options: Learning Objectives

Statins

Chemical Structure

Statins

Mechanism of Action

Statins

Dosing and Administration

Statins

Side Effects

Statins

Statin Intolerance

Statins

Efficacy and Safety: Therapy Results

Statins

Efficacy and Safety: Special Populations

Ezetimibe (Zetia)

FDA Approval, 2002

Ezetimibe (Zetia)

Efficacy and Safety: Monotherapy

Ezetimibe (Zetia)

Efficacy and Safety: Ezetimibe Plus Statins

Ezetimibe (Zetia)

Efficacy and Safety: SHARP (Study of Heart and Renal Protection - 2011)

PCSK9 Inhibitors

Side Effects

Niacin (Nicotinic Acid)

Chemical Structure

Niacin (Nicotinic Acid)

Side Effects and Contraindications

Niacin (Nicotinic Acid)

Efficacy and Safety: Word of Caution

Fibrates

Chemical Structure, MoA, and Administration: Fibrates

Fibrates

Patient Benefit

MTP and Oligonucleotide Inhibitors

Lomitapide

MTP and Oligonucleotide Inhibitors

Side Effects: Lomitapide and Mipomersen

MTP and Oligonucleotide Inhibitors

Efficacy, Safety, Meta-analysis

Bile Acid Sequestrants

Available Bile Acid Sequestrants (Bile Acid Binding Resins)

Emerging Therapies

Emerging Therapies Overview

Emerging Therapies

Still in Development: Anacetrapib and TA-8995

Emerging Therapies

Emerging Therapies that Target PCSK9

Emerging Therapies

Emerging Therapies: ETC-1002 (Bempedoic Acid)

Emerging Therapies

Emerging Therapies that Target Lp(A)

Treatment Guidelines: Introduction

Treatment Guidelines: Learning Objectives

Treatment Goals and Modalities

AACE 2012 Guidelines for Management of Dyslipidemia and Prevention of Atherosclerosis

Treatment Goals and Modalities

AACE 2012 Guidelines for Management of Dyslipidemia and Prevention of Atherosclerosis Overview

AACE 2012 Guidelines for Management of Dyslipidemia and Prevention of Atherosclerosis

Dyslipidemia and Prevention of Atherosclerosis

AACE 2012 Guidelines for Management of Dyslipidemia and Prevention of Atherosclerosis

Screening

AACE 2012 Guidelines for Management of Dyslipidemia and Prevention of Atherosclerosis

Follow-Up and Monitoring

Additional Recommendations and Position Statements

National Lipid Association (NLA) Recommendations for Patient-Centered Management of Dyslipidemia

Additional Recommendations and Position Statements

NLA Recommendations for Patient-Centered Management of Dyslipidemia

Additional Recommendations and Position Statements

NLA Recommendations for Patient-Centered Management of Dyslipidemia: Lipoprotein Levels

Clopidogrel Clinical Trials

ISAR CHOICE Study

Clopidogrel

Clopidogrel: Mechanism of Action

Introduction

Thienopyridines: Introduction

Clopidogrel Clinical Trials

ALBION Study

Clopidogrel

Clopidogrel: Approved Indications

Clopidogrel Clinical Trials

ARMYDA-2 Study

Clopidogrel Clinical Trials

CURRENT-OASIS 7: Results

Clopidogrel Clinical Trials

CURRENT-OASIS 7 Study

Learning Objectives

Clopidogrel Clinical Trials

Pretreatment Study

Clopidogrel Clinical Trials

CREDO Study

Clopidogrel Clinical Trials

ARMYDA-2: Conclusion

Clopidogrel

Clopidogrel: Dosage and Administration

Clopidogrel

Drug Interactions and Hyporesponse

Clopidogrel

Clopidogrel: Warnings

Clopidogrel

Clopidogrel: Warnings

Learning Objectives

Introduction

Introduction: Platelet Overview

Drug Therapy Introduction

Bleeding

GP IIb/IIIa Inhibitors

Mechanism of Action: GP IIb/IIIa Inhibitors

GP IIb/IIIa Inhibitors

GP IIb/IIIa Receptor Antagonists

GP IIb/IIIa Inhibitors

Approved Indications: Warnings

GP IIb/IIIa Inhibitors

Abciximab (ReoPro)

GP IIb/IIIa Inhibitors

Eptifibatide (INTEGRILIN)

GP IIb/IIIa Inhibitors

Tirofiban (AGGRASTAT)

Aspirin

Mechanism of Action: Aspirin as an Inhibitor

Aspirin

Mechanism of Action: Aspirin as a Blocker

Aspirin

Aspirin: Vascular Indications

Aspirin

Aspirin with Ibuprofen (NSAIDs)

Aspirin

Aspirin: Warnings

Dipyridamole

Dipyridamole: Mechanism of Action

Dipyridamole

Approved Indications

Dipyridamole

Dipyridamole : Warnings

Thienopyridines

Mechanism of Action: Thienopyridines

Thienopyridines

Warnings: Thienopyridines

Thienopyridines

Ticlopidine (TICLID)

Thienopyridines

Clopidogrel (PLAVIX)

Emerging Therapies

Phosphodiesterase III Inhibitors: Cilostazol (PLETAL)

Emerging Therapies

Therapies on the Horizon

Introduction

Introduction: ADP P2Y12 Receptor Antagonists

Ticlopidine

Ticlopidine: Mechanism of Action

Prasugrel

Prasugrel: Mechanism of Action

Ticlopidine

Ticlopidine: Approved Indications

Ticlopidine

Ticlopidine: Boxed Warning

Ticlopidine

Ticlopidine: Warnings

Ticlopidine

Replaced by Clopidogrel

Clopidogrel Clinical Trials

CREDO: Conclusion

Clopidogrel Clinical Trials

Non-ACS (including Stroke) Studies

Clopidogrel Clinical Trials

CARESS Study

Clopidogrel Clinical Trials

CARESS: Results

Clopidogrel Clinical Trials

MATCH: Conclusion

Prasugrel

Prasugrel: Mechanism of Action

Prasugrel

Approved Indications

Prasugrel

Dosage and Administration

Prasugrel

Boxed Warnings

Prasugrel Clinical Trials

JUMBO-TIMI 26 Study

Prasugrel Clinical Trials

JUMBO TIMI 26: Results

Prasugrel Clinical Trials

TRITON-TIMI 38 Clinical Trial

Prasugrel Clinical Trials

Objectives: Testing the Hypothesis

Prasugrel Clinical Trials

Objectives: Primary Endpoints

Prasugrel Clinical Trials

Primary Efficacy and Safety Data

Prasugrel Clinical Trials

Primary Efficacy and Safety Data: Net Clinical Benefit and Conclusion

Prasugrel Clinical Trials

Stent Thrombosis Sub-Analysis

Prasugrel Clinical Trials

Stent Thrombosis Sub-Analysis: Results and Conclusion

Prasugrel Clinical Trials

Early and Late Events (Landmark Analysis): Study Design

Prasugrel Clinical Trials

Early and Late Events (Landmark Analysis)

Prasugrel Clinical Trials

Recurrent Events Data

Prasugrel Clinical Trials

STEMI Population Data

Prasugrel Clinical Trials

STEMI Population Data: Conclusion

Prasugrel Clinical Trials

MI Analysis (Including Universal Definition)

Prasugrel Clinical Trials

MI Analysis (Including Universal Definition): Results

Prasugrel Clinical Trials

MI Analysis (Including Universal Definition)

Prasugrel Clinical Trials

Diabetes Data

Prasugrel Clinical Trials

Diabetes Data: Conclusion

Prasugrel Clinical Trials

PRINCIPLE-TIMI 44 Study

Prasugrel Clinical Trials

PRINCIPLE-TIMI 44: Results and Conclusion

Thienopyridines

Differences in Active Metabolite Generation

Plavix® vs. Effient™

Comparative PK/PD

Plavix® vs. Effient™

Comparative PK/PD: Clinical Implications

Plavix® vs. Effient™

Key Differences in Plavix® and Effient™ Label

Novel Oral Anticoagulants: Factor Xa Inhibitors: Rivaroxaban

Contraindications and Boxed Warning

Novel Oral Anticoagulants: Factor Xa Inhibitors: Rivaroxaban

Pharmacokinetics: Absorption

Rationale For Use of Novel Oral Anticoagulants

Overview of Anticoagulant Agents

Standard Agents: Overview

Fondaparinux

Standard Agents: Selected Clinical Studies

Vitamin K Antagonists (VKAs): Warfarin

Standard Agents: Selected Clinical Studies

Fondaparinux: Treatment of Deep Vein Thrombosis

Novel Oral Anticoagulants: Factor Xa Inhibitors: Apixaban

Apixaban: Dosage and Administration

Introduction

Introduction

Rationale For Use of Novel Oral Anticoagulants

Limitations of Traditional Rapid Acting and Traditional Oral Anticoagulants

Introduction

Introduction

Guidelines for Anticoagulant Therapy

Anticoagulation Therapy Indications

Guidelines for Anticoagulant Therapy

Atrial Fibrillation (AF): Guidelines for Anticoagulation Therapy

Guidelines for Anticoagulant Therapy

Venous Thromboembolism (VTE): Treatment Guideline Overview

Guidelines for Anticoagulant Therapy

Venous Thromboembolism (VTE): Uncomplicated Treatment

Guidelines for Anticoagulant Therapy

Complicated Venous Thromboembolism (VTE) Treatment

Guidelines for Anticoagulant Therapy

Venous Thromboembolism (VTE)

Guidelines for Anticoagulant Therapy

Venous Thromboembolism (VTE) Treatment Follow-Up and Secondary Prevention: Bridging and Perioperativ...

Standard Agents: Overview

Standard Anticoagulants

Standard Agents: Overview

Vitamin K Antagonists (VKAs)

Standard Agents: Overview

Unfractionated Heparin (UFH)

Standard Agents: Overview

Low Molecular Weight Heparin (LMWH)

Standard Agents: Overview

Low Molecular Weight Heparin (LMWH): Indications

Standard Agents: Overview

Aspirin

Standard Agents: Selected Clinical Studies

Selected Clinical Studies

Standard Agents: Selected Clinical Studies

Vitamin K Antagonists (VKAs): Warfarin

Standard Agents: Selected Clinical Studies

Unfractionated Heparin (UFH) and Low Molecular Weight Heparins (LMWHs)

Standard Agents: Selected Clinical Studies

Fondaparinux: Treatment of Pulmonary Embolism

Standard Agents: Selected Clinical Studies

Aspirin: Stroke Prevention in Atrial Fibrillation (AF)

Therapeutic Challenges and Unmet Needs

Therapeutic Challenges of Antithrombotic Treatment

Therapeutic Challenges and Unmet Needs

Vitamin K Antagonists (VKAs): Warfarin

Therapeutic Challenges and Unmet Needs

Warfarin: Monitoring and Anticoagulant Reversal

Therapeutic Challenges and Unmet Needs

Unfractionated Heparin (UFH)

Therapeutic Challenges and Unmet Needs

Low Molecular Weight Heparin (LMWH): Boxed Warning

Therapeutic Challenges and Unmet Needs

Low Molecular Weight Heparin (LMWH): Enoxaparin and Dalteparin

Therapeutic Challenges and Unmet Needs

Fondaparinux: Boxed Warning, Laboratory Monitoring, and Anticoagulant Reversal

Therapeutic Challenges and Unmet Needs

Aspirin: Warnings and Anticoagulant Reversal

Therapeutic Challenges and Unmet Needs

Table of Agents

Rationale For Use of Novel Oral Anticoagulants

Development and Advantages of Novel Oral Anticoagulants (NOACs)

Rationale For Use of Novel Oral Anticoagulants

Complexities of Novel Oral Anticoagulants (NOACs)

Use of Novel Oral Anticoagulants

Stroke Prevention in Atrial Fibrillation (AF)

Use of Novel Oral Anticoagulants

Stroke Prevention in Atrial Fibrillation (AF): Guidelines

Administration of Novel Oral Anticoagulants: Overview

Administration of Novel Oral Anticoagulants: Overview

Administration of Novel Oral Anticoagulants: Direct Thrombin Inhibitor: Dabigatran

Dabigatran Overview

Administration of Novel Oral Anticoagulants: Direct Thrombin Inhibitor: Dabigatran

Indications

Administration of Novel Oral Anticoagulants: Direct Thrombin Inhibitor: Dabigatran

aPTT, Renal Impairment, Special Considerations and Mechanism of Action

Administration of Novel Oral Anticoagulants: Direct Thrombin Inhibitor: Dabigatran

Clinical Pharmacology

Administration of Novel Oral Anticoagulants: Direct Thrombin Inhibitor: Dabigatran

Clinical Pharmacology: Pharmacokinetics

Administration of Novel Oral Anticoagulants: Direct Thrombin Inhibitor: Dabigatran

Contraindications, Boxed Warning, and Precautions

Novel Oral Anticoagulants: Factor Xa Inhibitors: Rivaroxaban

Overview: Rivaroxaban

Novel Oral Anticoagulants: Factor Xa Inhibitors: Rivaroxaban

Indications, Dosage and Administration

Novel Oral Anticoagulants: Factor Xa Inhibitors: Rivaroxaban

Use in Patients with Renal Impairment

Novel Oral Anticoagulants: Factor Xa Inhibitors: Rivaroxaban

Clinical Pharmacology: Pharmacodynamics, Laboratory Monitoring and Anticoagulant Reversal

Novel Oral Anticoagulants: Factor Xa Inhibitors: Rivaroxaban

Warnings, Precautions and Use in Pregnancy

Novel Oral Anticoagulants: Factor Xa Inhibitors: Apixaban

Overview: Apixaban

Novel Oral Anticoagulants: Factor Xa Inhibitors: Apixaban

Apixaban: Mechanism of Action

Novel Oral Anticoagulants: Factor Xa Inhibitors: Apixaban

Clinical Pharmacology: Pharmacodynamics and Anticoagulant Reversal

Novel Oral Anticoagulants: Factor Xa Inhibitors: Apixaban

Pharmacokinetics: Absorption

Novel Oral Anticoagulants: Factor Xa Inhibitors: Apixaban

Drug Interaction Studies

Novel Oral Anticoagulants: Factor Xa Inhibitors: Apixaban

Apixaban: Contraindications and Boxed Warning

Novel Oral Anticoagulants: Factor Xa Inhibitors: Apixaban

Apixaban: Warnings, Precautions and Use in Pregnancy

Summary of Agents

Summary of Agents

Current Therapies

Overview: Current Therapies for MS
Treatment of Acute Relapses: Severe Relapses: Therapeutic P...

Emerging Hypotheses on Treatment

Emerging Hypotheses on Treatment: Myelination-Targeted Antibodies
Cell Therapy
Human Stem ...